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ABSTRACT OF DISSERTATION 
 
 
 
DEVELOPMENT OF LUMINESCENT SENSING SYSTEMS WITH CLINICAL 
APPLICATIONS 
 
As the move towards the miniaturization of many diagnostic and detection 
systems continues, the need for increasingly versatile yet sensitive labels for use 
in these systems also grows.  Luminescent reporters provide us with a solution to 
many of the issues at hand through their unique and favorable characteristics.  
Bioluminescent proteins offer detection at extremely low concentrations and no 
interference from physiological fluids leading to excellent detection limits, while 
the vast number of fluorescent proteins and molecules available allows the 
opportunity to select a tailored reporter for a specific task. Both provide relatively 
simply instrumentation requirements and have exhibited great promise with many 
of the miniaturized systems such as lab-on-a-chip and lab-on-a-CD designs.  
Herein, we describe the novel employment of luminescent reporters for four 
distinct purposes.  First off, by combining both time and wavelength resolution we 
have expanded the multiplexing capabilities of the photoprotein aequorin beyond 
duel-analytes, demonstrating the ability to simultaneously detect three separate 
analytes. Three semi-synthetic aequorin proteins were genetically conjugated to 
three pro-inflammatory cytokines (interleukins 1, 6, and 8) resulting in aequorin 
labeled cytokines with differing emission maxima and half lives to allow for the 
simultaneous detection of all three in a single solution through the elevated 
physiological concentration range.  Secondly a semi-synthetic aequorin variant 
has been genetically enhanced to serve as an immunolabel and exhibited the 
ability to sensitively detect the acute myeloid leukemia marker, CD33, down to 
the attomole level in addition to improving aequorin imaging capabilities.  In the 
third example, the aequorin complex was rationally, genetically split into two 
parts and attached to the termini of the cAMP selective cAMP receptor protein 
(CRP) creating a genetically fused molecular switch.  The conformational change 
experienced by CRP upon the binding of cAMP translates into a loss of 
bioluminescent signal from aequorin and has shown the ability to respond linearly 
to cAMP over several orders of magnitude.  Lastly, through custom design, a 
reagentless, portable, fluorescent fiber optic detection system has been 
developed, capable of being integrated into the body through a heart catheter. 
The system was able to respond to changes in potassium concentration 
selectively, reproducibly and reversibly with a fast response time of one minute.   
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CHAPTER ONE 
 
STATEMENT OF RESEARCH 
  
 Luminescent sensing systems offer many advantages in a clinical, 
diagnostic, and research setting.  To that end, the first goal of this work was to 
employ and expand the use of the photoprotein aequorin for novel analytical 
applications.  The second goal of this work was to develop a compatible system 
for the fluorescent, real time monitoring of a desired analyte in a clinically 
relevant setting.   The overall hypothesis for this work is that: By altering, 
combining, and applying luminescent molecules in a new environment, novel 
luminescent sensing systems are developed that find relevance in a diversity of 
clinical and investigative areas. More specifically the photoprotein aequorin can 
be genetically manipulated and combined with chromophoric alterations to 
expand the number and type of detection platforms possible.  Additionally by 
incorporating luminescent optode membranes on the tip a fiber optic, new 
monitoring applications are made possible. 
-Chapter 3 describes the development of a competitive assay for three clinically 
relevant cytokines of interest through the use of three different semi-synthetic 
aequorin complexes to expand aequorin’s multiplexing capabilities beyond dual-
analytes.   
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-Chapter 4 shows how genetic engineering can enhance the ability of aequorin to 
be used as a label through the addition of a unique cysteine to an aequorin 
mutant.  The feasability was demonstrated through the detection and imaging of 
the acute myeloid leukemia cells and its surface antigen CD33. 
-Chapter 5 demonstrates aequorin’s unique ability to be genetically split and then 
structurally reformed.  The bioluminescence can be modulated through a cAMP 
assisted conformational change of cAMP receptor protein.   
-Chapter 6 details the development of a potassium ion sensor that is capable of 
being incorporated through a heart catheter to monitoring blood potassium 
changes in vivo, in real time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © Daniel F. Scott 2011 
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CHAPTER TWO 
 
INTRODUCTION 
Adapted with permission from:  Scott, D., Dikici, E., Ensor, C., Danuert, S., 2011.  
Bioluminescence and its Impact on Bioanalysis, Annual Reviews of Analytical 
Chemistry, 4, 297-319. Copyright 2011, Annual Reviews. 
Bioluminescence Background 
Bioluminescence is a natural phenomenon that has captivated the 
attention of mankind throughout human history.  The Greeks had a fascination 
with bioluminescence and Aristotle reported detailed observations of 
bioluminescence in nature.   Even earlier accounts of bioluminescence can be 
found in the legends of a number of ancient civilizations such as the Polynesian 
and Siberian (1-2).  Bioluminescence has been at the center of various types of 
legends and superstitions, a part of religious beliefs and ceremonies, and more 
recently, the focus of scientific explorations.  
Bioluminescence is the production and emission of light by a living 
organism.  It has been observed in a diverse collection of organisms including 
insects, bacteria, fish, fungi, plants and an assortment of marine invertebrates 
(see figure 1).  The functions of bioluminescence are just as varied, ranging from 
defense, predation, and communication to metabolic, in which it acts as a 
terminal oxidase (3).  In general, the basis for the generation of bioluminescent 
light stems from a biochemical internal reaction whereas the substrate of an 
enzyme or the chromophore of a photoprotein undergoes a reaction that results  
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Figure 1.  Several bioluminescent proteins are isolated from different organisms 
such as Photinus pyralis, and Aequorea victoria.  Reprinted with permission from:  
Laura Rowe, Emre Dikici and Sylvia Daunert, 2009. Engineering Bioluminescent 
Proteins: Expanding the Analytical Potential.  Anal. Chem., 81 (21), pp 8662–
8668.  Copyright American Chemical Society, 2009. 
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in the excitation of the electrons into a higher energy level, which upon relaxation 
results in the emission of a photon.  
Although the phenomenon of bioluminescence has been observed for 
thousands of years, it was not until more recently, roughly in the last 50 years, 
that the true analytical potential of bioluminescence started to be realized.  A 
renewed interest in bioluminescence was prompted by the discovery and 
isolation of aequorin and the green fluorescent protein (GFP) from the jellyfish 
Aequorea victoria by Osamu Shimomura in 1962 (4). Later on, Martin Chalfie 
cloned GFP(5), making it widely available to researchers for a multitude of 
chemical and biological applications, and Roger Tsien prepared a series of 
mutants with an array of wavelengths of emission that resulted in proteins 
fluorescing in most of the colors of the spectrum (6).  The applications that these 
proteins have found in biomedical research and bioanalysis are unprecedented.  
The importance and contribution of this discovery to major advances in science 
was recognized in 2008 when Osamu Shimomura, along with Martin Chalfie and 
Roger Tsien were awarded the Nobel Prize in Chemistry for the discovery and 
development of GFP (7).   
Advancement in photonics instrumentation has also enabled the use of 
bioluminescence proteins in a number of detection and imaging applications.  
Bioluminescence offers marked advantages in this area, exhibiting efficient 
quantum yields (8).  Moreover, given that the light generation is the result of a 
biochemical reaction, there is no need for an external excitation source, thus 
eliminating background noise associated with scattering from the source as well 
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as from autofluorescent molecules present in the sample (especially in 
physiological fluids).  Therefore, the use of bioluminescent proteins has been 
especially successful in applications and fields requiring high sensitivity.   
Advances in molecular biology have also greatly diversified the potential 
uses of bioluminescent proteins, which include their use as reporters and labels 
in intracellular ATP and Ca2+ detection, DNA and RNA hybridization assays, 
immunoassays, gene expression, whole-cell biosensors, bioluminescence 
resonance energy transfer (BRET) assays, and as labels for miniaturized 
systems such as lab-on-a-chip and lab-on-a-CD based instruments.   
Bioluminescent proteins  
Bioluminescent proteins are typically divided into two subgroups 
consisting of luciferases and photoproteins.  The mechanism of bioluminescence 
emission of luciferases is characterized by an enzyme-substrate reaction where, 
in the presence of oxygen, the luciferase oxidizes luciferin (substrate) resulting in 
the formation of a product that is in an electronically excited state, and whose 
subsequent relaxation is responsible for the emission of a photon (9) (figure 2).  
Thus, the amount of light emitted is proportional to the concentration of the 
luciferin present. 
Photoproteins, on the other hand, are capable of emitting light in a manner 
that is proportional to the concentration of the protein present.  This type of 
protein could be considered as a very stable form of an enzyme-substrate 
complex where the dissociated forms are not energetically favorable and thus,  
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Figure 2.  The ATP dependent reaction mechanism for the bioluminescence of 
firefly luciferase.  With ATP and Mg2+ as co-factors, luciferase catalyzes the 
oxidation of luciferin which results in an excited state luciferin.  When this excited 
state luciferin relaxes back down to the ground state, light is emitted 
corresponding the difference in the engery levels.   
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stay complexed and represent the primary light emitting component (10).  Both, 
bioluminescent enzymes and photoproteins have distinct advantages and the 
preferential use of one type over the other often depends on the need at hand.   
As mentioned above, bioluminescence occurs in a variety of terrestrial and 
marine organisms and, in vivo, bioluminescence serves numerous biological 
functions.  These functions range from feeding, mating, communication and 
concealment from predators (11).  Despite the abundance of bioluminescent 
organisms in the oceans, the number of bioluminescent proteins isolated and 
characterized from these organisms is surprisingly low, and consequently, their 
use in analytical applications is still fairly meager.  This review will focus on the 
known proteins and their use and contributions and advancements in bioanalysis.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
Some of the first and most extensively studied bioluminescent proteins are 
the luciferases found in certain beetles, particularly the firefly luciferase from the 
Lampyridaefamily.  This group of luciferases from terrestrial insects also includes 
the railroad worm (Phengodidae family) and click beetle (Elateridae family) 
luciferases.  These luciferases generate bioluminescent light emission by 
catalyzing a reaction where oxidation of D-luciferin in the presence of ATP and 
O2 results in an excited state, oxyluciferin, which upon relaxation emits a photon 
(12).  The bioluminescence light produced by firefly luciferase is observed as a 
broad band with a wavelength of emission that peaks at 560 nm (3).  These 
luciferases have found uses as labels in such applications as ATP assays for the 
estimation of total biomass, contamination of microorganisms, cell viability and 
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enzyme assays, and as a reporter gene in a variety of cellular and physiological 
investigations (13).   
The most abundant source of bioluminescent organisms, however, is 
undoubtedly, the marine environment.  A broad range of marine organisms 
exhibit bioluminescence (11, 14), but only a few of the bioluminescent proteins 
from these organisms have been employed in analytical applications.  Among 
those are the luciferases found in the marine copepod Gaussia princeps and the 
sea pansy Renilla reniformis.  These luciferases use coelenterazine as a 
substrate which, in the presence of molecular oxygen, undergoes an oxidation 
step that results in an excited form of coelenterazine, coelenteramide, that upon 
relaxation emits light (14).  The wavelength of emission maxima of the Renilla 
and Gaussia luciferases are almost identical, at 485 and 490 nm, respectively 
(15).  These luciferases have been employed in protein-protein interaction 
studies, BRET assays, and whole-cell biosensors, to name a few (16-18).     
As with their terrestrial counterparts, marine luciferases are the 
bioluminescent proteins better characterized.  In the marine bacterial luciferase 
from Vibrio fischeri and Vibrio harvey, the production of light is due to a two-step 
mechanism where the first step involves the reaction of luciferase bound to 
reduced flavin mononucleotide with oxygen to produce a peroxyflavin 
intermediate.  This intermediate then reacts with an aldehyde luciferin 
endogenous in the bacteria to form a second intermediate, whose decay 
generates the emission of bioluminescent light at a wavelength of ~490 nm (see  
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figure 3) (19).  An interesting aspect of this bioluminescent system is that the lux 
cassette gene (luxCDABE) is responsible for coding for not only the luciferase, 
but also the enzymes able to synthesize the necessary substrates for the 
bioluminescence reaction, as opposed to the luciferin synthesizing enzymes of 
other organisms, which are controlled by separate genes.    The incorporation of 
the entire lux cassette as a reporter gene in biosensor applications, results in 
systems where there is no need for the addition of the external luciferase 
substrate, thus creating self-reporting systems.  Such technology has been 
employed in the design and development of whole cell and protein-based 
biosensing systems capable of monitoring water toxicity, heavy metals, quorum 
sensing molecules (20), and organic compounds among others (21-24).   
The photoproteins aequorin (figure 4) found in the jellyfish Aequorea 
victoria, and obelin native of the hydromedusa Obelia longissima, differ from the 
luciferase proteins in their mechanism of bioluminescence emission.  The 
bioluminescence-emitting aequorin and obelin are formed by the apoprotein and 
an imidazo-pyrazine chromophore, coelenterazine.   In these photoproteins, the 
amount of bioluminescence generated is, therefore, proportional to the 
concentration of the protein.  In both proteins, coelenterazine resides in a 
hydrophobic pocket of the protein, and is oxidized in the presence of molecular 
oxygen to form an excited coelenteramide (see figure 5).  However, in aequorin, 
for example, the coelenterazine in the hydroperoxide form is tightly bound in a 
hydrophobic pocket that does not allow this oxidation.  Upon binding Ca2+, the 
protein undergoes a conformational change, allowing the oxidation of the  
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Figure 3. The reaction mechanism for the bioluminescence of bacterial 
luciferase.   The production of light is due to a two-step mechanism where the 
first step involves the reaction of luciferase bound to reduced flavin 
mononucleotide with oxygen to produce a peroxyflavin intermediate.  This 
intermediate then reacts with an aldehyde luciferin endogenous in the bacteria to 
form a second intermediate, whose decay generates the emission of 
bioluminescent light at a wavelength. 
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Figure 4.  The ribbon structure of the photoprotein aequorin.  The protein is 
composed of 4 EF hands highlighted by the different colors.   
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Figure 5.  The reaction mechanism for the bioluminescence of aequorin. In the 
presence of Ca2+- aequorin undergoes a conformational change, oxidizing 
coelenterazine in the process, which results in an excited state coelenteramide.  
The relaxation of this coelenteramide back to the ground state is accompanied by 
the release of a photon. 
 
  
14 
 
coelenterazine and subsequent conversion into a highly unstable dioxetanone 
intermediate.  This intermediate then loses CO2 yielding an excited enolate anion 
of coelenteramide, which upon relaxation produces a flash of light at 469 nm (25-
26).  The relaxed coelenteramide is still held by the photoprotein and is 
releasedvery slowly; if excess coelenterazine is added to the initial solution, the 
resulting light intensity will be directly proportional only to the amount of 
photoprotein in the sample (25).  Since aequorin is a Ca2+-regulated 
photoprotein, it was initially employed as a probe for monitoring of intracellular 
Ca2+, but recently its use has been greatly expanded to other applications, 
among those hybridization and binding assays (10, 27).   
Analytical Applications of Bioluminescence 
As mentioned previously, bioluminescent proteins can provide the 
technology necessary to quantify extremely low concentrations of a desired 
analyte with the required sensitivity and reproducibility essential to today’s 
scientists. Thus, it comes as no surprise that the use of these proteins has 
exploded recently in an abundance of different detection systems and methods.  
These includeassays for Ca2+ and ATP, as well as nucleic acid quantification and 
hybridization assays, and immunoassays, among other binding assays.  In 
addition, bioluminescence has also been employed in resonance energy transfer 
and protein-protein interaction studies.   
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ATP Assays: Quantifying Energy Production  
Many luciferase enzymes require ATP to catalyze the oxidation reaction of 
the luciferin substrate.  In these cases, the absence of ATP blocks the 
bioluminescence reaction.  Based on this premise, researchers have developed 
highly sensitive bioluminescent assays for the detection of ATP.   For example, it 
has been shown that by employing firefly luciferase, ATP can be measured down 
to 0.01 fmol (28).  A variety of different format assays have been implemented to 
date.  A rapid screening test for to determine levels of ATP produced by 
contaminating fungi, bacteria, and yeast in food and feeds was developed by 
employing firefly luciferase.  In this assay, the amount of light emitted was shown 
to directly correspond to the microbial number (29).  With the increasing 
prevalence of multidrug resistant organisms, the ability to quickly screen a 
number of drugs for their effectiveness against different organisms would provide 
valuable information in the clinical setting (30-31).  Lafond et al. have worked 
towards using bioluminescent assays for ATP for the rapid determination of 
antibiotic susceptibility.   They were able to use the ATP assay in conjunction 
with adenylate kinase and quinine:NAD(P)H oxidoreductase in a parallel assay to 
demonstrate the ability to rapidly check for antibiotic resistance, shortening the 
investigation time to 6 hr while 24 hr of incubation is currently required.  The 
future prospects include the automation of the system in a microplate format to 
allow for more high throughput screening applications (32).  These are just a few 
of the examples of the bioluminescence ATP assays, as they have also been 
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employed for other hygiene (33), cytotoxicity (34), microbiological, drug discovery 
(35) and enzymatic assay applications (13).   
Intracellular Calcium Ion Detection: Illuminating Signal Transduction 
Pathways   
Similar to the initial use of luciferase for ATP measurements, the 
photoprotein aequorin was also first employed for the detection of its cofactor, 
Ca2+.  Aequorin was both injected into cells and expressed in vivo to monitor 
intracellular Ca2+ fluctuations in a variety of different cellular locations and in 
response to different external stimuli (27, 36). Two recently published book 
chapters by Michelini et al. and Villalobos et al. discuss, in detail, the 
methodologies and the instrumentation required for the imaging of Ca+2 in vivo 
(37-38).   The determination of Ca2+ concentrations in physiological fluids and 
cells is important because of the role that this ion plays in cellular signaling 
events.  The release of Ca2+ can be triggered by the activation of G-protein 
receptors and ion channels in the initiation of signal transduction mechanism in 
the cell.  It is important to understand the mechanism of action of these receptors 
and ion channels and their interaction with Ca2+ to elucidate signaling pathways 
as well as to design and develop new drug targets (39). Thus, as the need for 
faster, more efficient detection methods capable of high throughput screening 
continues to progress, the inherent advantages of bioluminescence have been 
recognized by the recent use of aequorin in a high throughput screening for Ca2+ 
with a microplate reader setup.  Menon et al. (40) intracellularly expressed apo-
aequorin alongside a chimeric G-protein and a G-protein-coupled dopamine 
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receptor and used the cells to screen 8,106 compounds as potential drugs 
targeting G-protein coupled receptors and ion channels.  Validation of this 
method and comparison with the current high throughput screening method of 
choice for the Ca2+ ion, a fluorescence based system, demonstrated similar 
performance with regard to the identification of positive hits.  However, the 
bioluminescent-based system presents some advantages in that it is more cost-
effective, has better reproducibility and a decreased number of false positives, 
most probably due to the lack of interference from autofluorescent compounds 
and excitation source.  
Bioluminescence in Genetics:  The Importance of DNA Detection. 
Nucleic acids are the building blocks of the macromolecules DNA and 
RNA, and as such, they play a vital role in the function and replication of living 
organisms.  DNA forms the basis of the genetic code that defines both our 
genotype, and later on our phenotype.  In other words, DNA dictates, for 
example, what we look like and whether or not we may be carriers of a genetic 
disorder.  In order to determine whether an individual is a carrier of a hereditary 
disease, it is necessary to establish the presence of harmful mutations in the 
DNA present in the affected chromosomes and determine their concentrations.  
Nucleic acids are present and experience changes at extremely low 
concentrations, which prompt the development of new emerging technologies 
based on bioluminescent detection.  These methods afford the low detection 
limits needed for measuring nucleic acids (41-42).  There are methods based on 
luminescence, i.e., real-time quantitative polymerase chain reaction (Q-PCR), 
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that have provided significant advances to the field.  Briefly, Q-PCR consists of 
designing an oligonucleotide probe specific for the target DNA labeled with both 
a fluorescent probe and a related quencher molecule.  The labeled 
oligonucleotide anneals to the target DNA, and as the polymerase progresses 
along the DNA strand it cleaves off the labeled probe, thus increasing the 
distance between the fluorescent probe and the attached quencher, which results 
in a subsequent increase in the observed fluorescent intensity (see figure 6).  
Drawbacks of this method include its costs, and the need for the preparation and 
labeling of the specific fluorescent nucleotide probes.  A bioluminescent 
alternative has been developed utilizing the bioluminescence regenerative cycle 
(BRC).  The premise behind the method involves the quantification of the 
pyrophosphate molecules released during the polymerization of the nucleic acids 
by the respective polymerase, which directly corresponds to the number of target 
molecules present.  The released pyrophosphate is converted to ATP by an ATP-
sulfurylaseenzyme, which then firefly luciferase can use to generate 
bioluminescence in the presence of luciferin (see figure 7).  Additionally, after the 
ATP is used for the emission of light by the luciferase it is regenerated back to a 
pyrophosphate molecule making the recycling and amplification of the signal 
from one pyrophosphate molecule possible.  It was shown that at a concentration 
of 1x10-8 M pyrophosphate, the amount of light produced at a given time interval 
is proportional to the number of nucleic acid molecules in a sample.  This 
translates to a detection limit of 1 amol of DNA in a solution, allowing potential  
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Figure 6.  Schematic depiction of real time PCR the fluorescent equivalent to Q-
PCR. The polymerization of the DNA cleaves off the quencher molecule, which 
allows the fluorescence from the fluorophore to be observed.  The intensity of 
light from the fluorophore will be proportional to the amplification of the DNA. 
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Figure 7.  Schematic depiction of bioluminescence regenerative cycle (BRC).  
The premise behind the method involves the quantification of the pyrophosphate 
molecules released during the polymerization of the nucleic acids by the 
respective polymerase, which directly corresponds to the number of target 
molecules present.  The released pyrophosphate is converted to ATP by an ATP-
sulfurylaseenzyme, which then firefly luciferase can use to generate 
bioluminescence in the presence of luciferin. 
  
21 
 
applications in gene expression, DNA and RNA quantification and single 
nucleotide polymorphism detection assays (43).   
Additionally, with the sequencing of the human genome in 2003, single-
nucleotide polymorphisms (SNPs) have recently surfaced as a potential marker 
for disease susceptibility and have been shown to be useful for monitoring drug 
effectiveness and side effects.  Thus, the ability to quickly monitor and recognize 
the SNPs is valuable with applications in clinical medicine, genome drug 
discovery and personalized medical treatment (44-45).   In a method similar to 
the previously mentioned BRC, a bioluminescence pyrophosphate assay has 
also been used for SNP detection.  Here the pyrophosphate released by the DNA 
polymerization from a specific primer after the polymerization to the target DNA is 
converted to ATP by pyruvate phosphate dikinase, which can also be quantified 
by firefly luciferase bioluminescence.  This method was capable of the 
identification of SNPs in both the p53 and K-ras genes (46).  Variations in the 
mannose-binding lectin gene, a genetic defect associated with increased 
susceptibility to infection and autoimmune disorders, have also been identified 
using aequorin as the reporter in genotyping tests (45).   
During the late 20th century, the popularity of solution hybridization assays 
along with the need to replace radioisotopes as labels in DNA and RNA 
detection, non-radiometric labeling options became preferred over the traditional 
radiolabels.  As mentioned earlier, bioluminescence offers the sensitive detection 
desired without the safety issues that radioisotopes impose (47-48).  In general, 
a bioluminescent protein is attached to the oligonucleotide of interest that is 
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complementary to an immobilized or target oligonucleotide sequence.  A 
potential limitation of this method is inactivation of the bioluminescent protein 
upon conjugation to the oligonucleotide.  However, a recent study has shown that 
this limitation can be overcome by using site-specific attachment methods.  For 
example, Nagatsuki et al attached an oligonucleotide to a cysteine of luciferase 
without adversely affecting the luminescent activity or the selectivity of the probe 
(49).  In another study, the photoprotein aequorin was employed for the sensitive 
detection of the malaria parasite Plasmodium falciparum.  The assay was based 
on a competition between free target DNA and an aequorin-labeled DNA 
molecule.  A genetically engineered aequorin was attached to the DNA 
oligonucleotide through a biotin-streptavidin interaction.  Detection limits of 3 
pg/µL in human serum were achieved, which fall within the range needed for 
diagnosis and management of malaria.   The most important advantage of this 
method is that there is no need for PCR amplification of the target DNA, thus 
rendering an assay that can be prepackaged and used in a microtiter plate 
format allowing faster throughput analysis of a large number of samples.  In 
addition, this assay offers advantages in terms of automation and the capability 
of use in developing regions and remote locations as compared to the current 
light microscopy technique for the parasite detection (50). 
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Driving the Detection of Biomolecules to the Lower Limits: Highly Sensitive 
Bioluminescence Immuno- and Binding Assays in Biomedical Analysis  
In simple terms, an immunoassay is a method that measures the 
concentration of a species of interest within a complex biological matrix by 
employing biological reagents that display molecular recognition toward each 
other.  In order to achieve the detection of a target analyte in a complex 
biological matrix, the method employed needs to be exceptionally selective.  In 
immunoassays this selectivity is usually achieved by using antibodies raised 
against the analyte of interest, while in competitive binding assays the selectivity 
is provided by a binding partner, often a binding protein or a receptor, that 
displays high affinity for the analyte-ligand.  Another issue to be taken into 
account when performing analysis in biological matrices is the potential low 
concentrations of analyte in the sample, which drives the choice for use of 
exceedingly sensitive labeling strategies.  In the early times of immunoassays 
development, the required high sensitivity was reached by employing 
radionucleotides.  Given the undesirable properties of radioactivity, researchers 
started to search for less dangerous alternatives by using electrochemical and 
optical methods.  To that end, the number of applications of bioluminescent 
proteins as sensitive labels in immunoassays has increased dramatically in 
recent years (8, 47, 51-53). Bioluminescent proteins can be used for 
immunoassays either in a sandwich type or competitive assay format.  The 
sandwich immunoassay consists of an antibody labeled with a bioluminescent 
protein which is used to quantify a target analyte bound by a separate antibody 
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attached to a solid support.  As the amount of analyte in the solution increases so 
does the observed bioluminescent signal, as more labeled antibodies are able to 
bind to the analyte.  In a competitive immunoassay format, the analyte of interest 
is labeled directly with the bioluminescent protein and competes with free 
unlabeled analyte in solution for a limited number of analyte-binding sites on the 
antibody.  Thus, the amount of light produced is indirectly proportional to the 
amount of analyte present in a given sample. An increased amount of analyte 
results in fewer free sites on the antibody for the binding of the labeled analyte, 
which results in a smaller bioluminescent signal.   In both cases, dose-response 
or calibration curves can be generated that correlate the amount of 
bioluminescence signal produced with the concentration of analyte present in the 
sample. 
 The conjugation of the bioluminescent protein to the analyte or antibody 
can be accomplished by either chemical or genetic conjugation methods.  
Chemical conjugation offers the convenience of the ability to use a single protein 
label for a broader range of applications by only altering the molecule to which 
the bioluminescent protein is attached, without having to express and purify a 
different protein each time. Traditionally, using chemical conjugation to label 
luciferases has been limited due to resulting loss of luciferase activity.  However, 
conjugation through a biotin-streptavidin binding pair has been shown to be an 
effective method for maintaining the bioluminescence activity of luciferase.  A 
biotinylated Cypiridina luciferase was used for a sandwich immunoassay for α-
interferon with a linear range of detection of 7.8-500 pg/mL, demonstrating the 
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ability of the enzyme to provide sensitive and versatile detection (54).  
Interestingly, aequorin is more amenable to chemical conjugation than some of 
the other bioluminescent proteins. Although the activity can be adversely affected 
by chemical modification, the residual bioluminescence activity still allows for its 
effective use as a label in assay development. One such example involves the 
use a genetically modified aequorin with a unique cysteine that was recently 
used to chemically label α-fetoprotein antibody, a serological marker of liver 
cancer.  The assay developed was capable of α-fetoprotein detection in the 0.02-
200 ng/mL range (55). There are numerous other examples where aequorin has 
been incorporated as a label in immunoassays and has yield excellent methods 
for the determination of a variety of physiologically relevant analytes such as 
cortisol, thyroxine, and 6-keto-prostaglandin-F1-α, thus demonstrating the broad 
applications of aequorin in bioanalysis (56).   
 Genetic conjugation offers advantages such as a known one to one 
conjugation ratio and reproducible batch-to-batch production of the labeled 
probe.  To accomplish this, the bioluminescent protein’s coding gene is placed in 
frame with the target protein or peptide’s coding sequence. Thus, after 
transcription and translation a single fusion protein consisting of the two proteins 
is created.  An example of such a strategy can be seen in the angiotensin II 
assay in which an angiotensin II-aequorin fusion protein competed with free 
angiotensin in human serum and resulted in a detection limit of 1 pg/mL (57).  
Fusion proteins with obelin and luciferases have also been developed for a 
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variety of applications including streptavidin fusion proteins for biotin 
conjugations and assays for IgGs and other proteins of interest (52). 
Designer Proteins:  Split Bioluminescent Proteins and Molecular Switches 
Proteins can be genetically manipulated by using an array of strategies 
encompassing fusions, site-directed and random mutagenesis, insertions, 
deletions, incorporation of unnatural amino acids into their structures, and even 
splicing.  For the latter strategy, a protein is spliced or split in two fragments, 
which usually causes total or significant loss of its original activity, which is 
regained when the two fragments recombine.  The proteins selected need to be 
able to regain their original activity or close to it, by either spontaneously 
reassemble or by coming in close contact via the help of a second protein.   
Researchers have utilized these strategies to split bioluminescent proteins into 
fragments and employed them to prepare molecular switches, protein 
complementation and protein-protein interaction assays (58-61).  In all these 
assays, an external process such as analyte binding or protein interaction to 
reposition the fragments, modulating the bioluminescence emission of the 
protein, which can be related to the concentration of analyte present, and thereby 
allowing quantification or visualization of the event (see figure 8).  The discovery 
of theinteraction between the split bioluminescent proteins and other analytes 
and/or proteins is an interesting and versatile one as it can form the basis for the 
design of a plethora of assays by choosing different methods to split and 
recombine the proteins. 
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Figure 8. Schematics of bioluminescent A. molecular switches and B. split 
complementation assays.  Molecular switches utilize a molecular recognition 
mediated conformational change of a binding protein to alter the position of the 
two fragments a reporter protein to modify the output signal.  Split 
complementation assays rely on protein-protein interactions to facilitate the 
positioning of the reporter protein fragments into close proximity.   
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Many proteins in their natural environment require specific interaction and 
recognition of other protein complexes to be activated or to perform a function.  
Much still needs to be learned about these processes, as they are key to many 
fundamental events such as cellular functions, energy storage, on-set of disease, 
etc.  Thus, new technologies that can provide insight into these interactions and 
mechanisms of action of proteins should advance the understanding of cellular 
events.  To that end, protein complementation assays and protein-protein 
interactionshave been developed.  An interesting example, albeit somewhat 
complicated with respect to its design involves splitting firefly luciferase and 
attaching, by genetic means, the N-terminal and C-terminal of the luciferase 
fragments to the N- and C-termini of the split intein containing DnaE, respectively 
to develop an assay for insulin. These fusion proteins were linked to a protein of 
interest, in this case the insulin receptor substrate 1 (IRS-1), which was attached 
to the N-terminal luciferase-DnaE and its target protein, the SH2 domain of PI 3-
kinase, which was linked to the C-terminal luciferase-DnaE.   The DnaE intein is 
known to excise out and ligate the flanking external proteins together, in this case 
the N- and C-terminal luciferase complexes.   It was shown that the insulin 
induced phosphorylation of IRS-1 led to the recognition of the SH2 domain, 
bringing the DnaE fragments together, followed by the splicing of the luciferase 
fragments to reform the bioluminescently active luciferase.  The corresponding 
light can then be directly correlated with the concentration of insulin in a dose-
dependent manner (62).  A similar mechanism with Renilla luciferase further 
demonstrated the versatility of such systems (63).   
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The study of protein-protein interaction employing protein splicing is not 
limited to intein-mediated reassembly as in the case described above.  Indeed, 
Renilla luciferase has also been employed for such studies without the intein 
excision.  Specifically, a genetically modified Renilla luciferase was split and 
attached to the Y941 peptide of the aforementioned IRS-1 and N-terminal SH2 
domains, demonstrating an ability to detect low levels of insulin from pM to nM 
range (64).  Small molecule mediated protein-protein interaction has also been 
investigated using the rapamycin-mediated interaction between the human 
FK506-binding protein and the FKBP12-rapamycin binding domain (65).  Given 
the large number of potential target proteins for these types of assays, potential 
applications are limitless and include high throughput drug screening and 
investigation of specific pathways in signaling events, among others.   
 More recently, a molecular switch that employs the bioluminescent protein 
aequorin as its signal generator has been reported.  This molecular switch differs 
from the protein complementation in that both components of the split 
bioluminescent proteins are attached to a single recognition protein.  The two 
fragments of aequorin are genetically attached to the termini of the recognition 
protein, which upon the specific binding of a target analyte undergoes a 
conformational change, altering the orientation of the two aequorin fragments.  
This leads to an “on-off” type switch where the binding of the analytes can either 
turn the bioluminescence on or off, allowing for the quantification of the specific 
analytes.  To this end an aequorin molecular switch for the detection of glucose 
was developed by inserting the DNA coding sequence of glucose galactose 
30 
 
binding protein (GBP) into the aequorin coding sequence, yielding a unique 
fusion protein with the two fragments of aequorin attached to the N- and C-
termini of GBP.  GBP, upon the selective binding of glucose, undergoes a 
conformational change to bring the two fragments of aequorin in close enough 
proximity to reassemble the bioluminescence complex, turning the 
bioluminescence on.  The switch showed selective response to glucose over 
other sugars, and responded linearly at physiological levels of glucose (66).   
Sensing with Living Cells: Whole-Cell Biosensors Based on 
Bioluminescent Reporters 
 Protein- based assays and biosensing systems have a proven record of 
excellent performance in the detection and quantification of analytes in different 
types of samples, those being biomedical or environmental toxins (67).  A 
disadvantage of these systems is that they are not poised to indicate the 
bioavailability of said toxins, and therefore, researchers cannot gain information 
regarding information related to cytotoxicity, genotoxicity, or the synergistic toxic 
effects of these environmental pollutants upon living systems.  Bioavailability and 
effect on cellular functions can only be obtained when employing whole-cell 
biosensors, which can gain insight into living cells, and help understand how a 
particular substance or group of substances will impact living organisms (68-70).  
In general, bioluminescent whole cell sensors are based on the principle that 
either a specific analyte or group of analytes will interact with living cells 
containing a gene for a bioluminescent protein.  The interaction of the analytes 
with the cells will then either “turn” the bioluminescent property of the cells on or 
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off, depending on the type of system employed.  Systems employing the “lights 
off” approach are typically applied in toxicity assays.  In this assay format, a 
naturally bioluminescent species, such as V. fisherii, is exposed to a water 
sample.  The premise of this type of toxicity assays, also known as cell-death 
based assays, is the known sensitivity of V. fisherii to a variety of environmental 
toxins.  The presence of a toxin in the water sample can interfere with the 
metabolic pathway of the cell or block the expression of luciferase, which is 
observed as a decrease in the bioluminescence signal generated by the 
bioluminescent organism.  Similar strategies have incorporated the luxCDABE 
cassette into different microorganisms including E. coli, P. fluorescens, and 
cyanobacteria, increasing the versatility of the whole cell sensing systems (71).  
For the “lights on” systems the expression of a bioluminescent gene, such as the 
luxCDABE cassette, is controlled by a selective promoter or a regulatory gene.  
Thus, when the target analyte is present, the expression of Lux proteins and 
subsequent bioluminescence is turned on to produce the bioluminescent signal 
(see figure 9).  The specific DNA promoters allow the cells to be engineered to 
detect specific toxins, including heavy metals such as cadmium, lead, copper, 
and mercury among others, antibiotics, aromatic and other organic compounds, 
and quorum sensing molecules to name a few (20, 72-78).  These types of 
biosensing systems have had an important impact in environmental analysis as 
well as in drug and cell screening in pharmacological and biomedical 
applications. 
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Figure 9.  A schematic of whole cell bioluminescent sensors.The binding of an 
analyte to the regulatory protein turns on the transcription of the lux cassette 
gene and translation of the light producing proteins.  Thus, the amount of light 
produced will be directly proportional to the concentration of analyte. 
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The Achilles’ heel of living cell biosensing systems, which limits their field 
applications, is their long-term stability and the somewhat difficulty of their 
transport.  To overcome these problems, the Daunert group proposed the use of 
sporulating microorganisms as the living cells that harbor the chosen sensing 
system.  For that, they used sporulating bacteria such as B. subtilisand B. 
megateriumfor the development of these sensing systems for arsenic and zinc. 
Spores can be stored for very long periods of time preserving its genetic material 
intact.  Under favorable environmental conditions, spores can be germinated to 
generate viable and metabolically active cells during many cycles.   To validate 
their hypothesis they employed a whole cell bioluminescent biosensing system 
based on reporter gene strategies capable of detecting arsenite.  The data 
obtained demonstrated that after either six-months of storage or three cycles of 
sporulation/regermination, the sensing system retained its analytical performance 
in terms of detection limit, dynamic range and reproducibility, thus demonstrating 
the feasibility of employing spores as a means of long term storage and 
transportation of whole-cell biosensors(79-80).  Storage strategies of this type 
could play a key role in enabling the use of whole cell sensing systems in on-site 
and field applications where the systems risk exposure to harsh or suboptimal 
conditions.   
Taking a Cue from Nature: Bioluminescence Resonance Energy Transfer 
Assays 
 Bioluminescence resonance energy transfer (BRET) is a naturally 
occurring phenomenon which was first discovered in marine organisms (81).  In 
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nature, there are plenty of examples of bioluminescence as a source of excitation 
of an acceptor protein that results in the emission of light at a different 
wavelength than that of the donor protein.  Perhaps the best example of a 
bioluminescent protein emitting light to excite a second protein is that of the 
pairing of the photoprotein aequorin and GFP.  In nature, in the jellyfish of the 
Aequorea family, aequorin and GFP reside in photocytes located in the umbrella 
of the jellyfish. Under certain circumstances that cause stress to the organism 
and when in cold deep dark locations of the ocean, the aequorin of the jellyfish 
emits bioluminescent light, which in turn via a radiationless energy transfer it 
excites GFP, which causes the now well-known and characterized typical 
emission of green fluorescence.  Taking a cue from nature, researchers have 
designed BRET based systems that resemble those found in nature, where the 
energy produced by a bioluminescent protein is transferred from this donor 
molecule, to an acceptor over short distances.   For the transfer to be effective 
this distance must typically be 10 nanometers and the bioluminescent donor 
protein emission profile must have good spectral overlap with the fluorescent 
acceptor molecule’s absorption profile (15).    BRET offers advantages over 
fluorescence resonance energy transfer (FRET) because it does not require an 
external excitation source.  Therefore, it can be used in cells that are 
photosensitive, and also in cells exhibiting autofluorescence.  The application of 
BRET also reduces the photobleaching problems associated with the 
fluorophores due to constant bombardment with high intensity sources.  Since 
the donor and acceptor must be in close proximity, BRET has been employed for 
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the study of various protein-protein interactions (82-84), receptor-ligand 
interactions (16), conformational change studies (85-86), and RNA detection and 
quantification (47) in a variety of applications.  The analytical applications of 
BRET have been the subject of recent reviews, and therefore, herein, will only be 
briefly covered (15, 87-88).   
 An interesting recent report described a novel biomineralization approach 
for the development of a near-infrared (NIR) light-emitting BRET complex.  The 
emission of NIR light is advantageous in deep tissue imaging, thus, a NIR BRET 
complex should have a plethora of applications in medicine.  Biomolecules have 
been used previously as a bottom-up control of inorganic nanostructure 
synthesis, however, in the biomineralization approach proposed the biomolecules 
serve a dual function, (1) as a template for nanostructure formation, and (2) as 
an active participant in the production of NIR light.  In this work, a mutant Renilla 
reniformis luciferase acted as a template for the growth of PbS quantum dots.  It 
was shown that the presence of luciferase was necessary as a template for the 
quantum dot configuration.  The luciferase activity was preserved during this 
process, so that the addition of coelenterazine light was produced in the NIR 
region.  The purified Renilla reniformis luciferase typically shows an emission 
maximum ~480 nm. This emission wavelength was still observed in the quantum 
dot complex; however, the intensity of the emission was significantly reduced 
compared to that of luciferase outside of the quantum dot, while emission in the 
NIR region appeared.  This confirmed that there was a radiationless transfer of 
the energy from luciferase to the PbS quantum dot that yield the NIR emission.  
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This is an important example of coupling biological materials with inorganic ones, 
and broadens the scope of use of these types of hybrid structures in a wide 
range of fields (89).   
Killing Two Birds (or More) with One Stone:  Multianalyte Detection 
 One area where the use of bioluminescence has been limited in relation to 
other optical methods, such as fluorescence, is in multiplex detection.  
Multiplexing, or detecting multiple analytes within a given sample simultaneously 
has received much attention in recent years.  To date, the reporters most utilized 
for multiplex assays are fluorescent compounds.  Fluorescent reporters are 
available throughout the visible light region making the differentiation of signals 
from several different sources possible.  Many of the bioluminescent proteins, 
however, exhibit broad emission profiles in similar regions impeding the 
discernment of multiple signals.  The ability to use bioluminescent labels for 
multiplexing assays would offer advantages for many technologies requiring high 
sensitivity and low detection limits, such as miniaturized devices and high 
throughput screening assays.  Great strides have recently been made in this 
area due to extensive mutagenesis studies performed on the bioluminescent 
proteins aequorin and luciferase as well as with the combination of multiple 
proteins.  Firefly luciferase natively emits light with a maximum at around 560 nm 
(3). Through site directed mutagenesis, key amino acids were altered, shifting 
the emission maximum towards the red region at 615 nm and in the blue 
direction to 549 nm (90).  With a 66 nm difference in emission maxima, the 
development of a dual analyte assay was possible.  Further detailed 
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investigations on the mechanism of bioluminescence emission of the protein led 
to the understanding that the wavelength of light emitted is a result of the degree 
of molecular rigidity of the excited state species, affected by the interacting amino 
acids.  This gained information laid the foundation for further tuning of the 
emission characteristics of luciferase (91).  Another method of altering the 
emission maximum through the incorporation of non-natural amino acids has 
also shown promise, shifting the maximum to 603 nm (92).   
An interesting approach to multianalyte detection is the so called “self-
illuminating quantum dot conjugates”.  This methodology developed at the 
Gambhir laboratory at Stanford University involves the conjugation of different 
quantum dots to Renilla luciferase.  The bioluminescence energy transfer 
between the luciferase and the quantum dots results in different colors of 
luminescence, which can be used to image cellular events or detect more than 
one analyte simultaneously (93-94). 
The deep oceans are full of bioluminescent organisms that are not fully 
studied, catalogued, or are yet to be discovered.  The growing collection of 
available bioluminescent proteins with different wavelengths of emission will offer 
an alternative to use genetic engineering to create proteins for use in multiplex 
analysis.  Ito et al. employed two natural proteins, namely aequorin and 
luciferase that emit at different wavelengths, in the development of a dual analyte 
sandwich immunoassay for prostate specific antigen/α-fetoprotein and prostate 
specific antigen/prostatic acid phosphatase pairs.  The assay utilized aequorin to 
label one antibody and firefly luciferase to label the other.  The bioluminescence 
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of both proteins was triggered simultaneously by adding Ca2+ and D-luciferase to 
the wells in a microtiter plate.  The signal emitted by aequorin was measured 
individually first, followed by that of luciferase detection. Both measurements 
were completed in 4 s. The assay showed high sensitivity and its performance 
correlated well with that of commercially available detection kits (95).   
 It has been also reported that the photoprotein obelin has also been 
spectrally tuned by altering the amino acid interactions with its chromophore, 
coelenterazine.  Obelin, which natively emits light at a 491 nm wavelength of 
emission, was genetically engineered to emit at 493 and 390 nm.   Mutations of 
positions W92F and H22E of the protein sequence yielded the obelin mutant with 
the 390 nm maximum, and a Y193F mutation resulted in the 493 nm variant.  
The proteins were used to label antibodies for the detection of the hormones 
hFSH and hLH, which are useful for the evaluation and diagnosis of diseases 
dealing with gonadal function.  The light emitting reactions were triggered by the 
addition of Ca2+, and the assay was able to achieve comparable detection levels 
to those obtained with radioimmunoassay techniques (96).   
 Similarly, aequorin has undergone extensive genetic modifications in the 
form of random and rational mutagenesis in the search for aequorin variants with 
a wide range of spectral characteristics.  It should be noted that variations in the 
chemical structure of aequorin’s chromophore, coelenterazine, also play a major 
role in affecting the mechanism of bioluminescence emission, and ultimately in 
altering the wavelength of emission of aequorin.  Pairing aequorin with different 
natural and synthetic coelenterazines offers another avenue, in addition to 
39 
 
mutagenesis of the protein, by which the spectral characteristics of aequorin can 
be tuned (97).  A large library of such semi-synthetic aequorin variants has been 
prepared and catalogued that display bioluminescence emission wavelengths 
that range from 448 nm to 519 nm (98).  It is noteworthy to point out that because 
aequorin has a bioluminescence emission with flash-type kinetics, altering the 
structure of the protein and pairing it with different celenterazines results in an 
alteration of the decay lives of the protein. Wild type aequorin paired with native 
coelenterazine typically exhibits flash-type kinetics with a short half-life of ~ 2s.  
In contrast, aequorin mutants paired with the coelenterazine i analog showed 
half-lives ranging from 11.8 to 50.1 s, which are significantly longer than the 
majority of the other semi-synthetic aequorin combinations (98).   
Non-natural amino acid incorporation into aequorin has also recently been 
reported as an alternative method of spectral tuning showing a shift in the 
emission maximum up to 517 nm (99). In this case, four non-natural amino acids 
were site-specifically incorporated into aequorin at amino acid positions 82 
through the use of a specially designed tRNA and an amber codon.  The 
introduction of the non-natural amino acid at a critical position within the 
aequorin’s hydrophobic pocket where coelenterazine resides, resulted in altering 
the protein’s interaction with coelenterazine, and as explained above this 
alteration resulted in a shift of the bioluminescence emission wavelength. An 
array of bioluminescence emissions with diverse spectral characteristics were 
recorded when the non-natural aequorin variants were combined with synthetic 
coelenterazines.   
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The aequorin variants paired with different coelenterazine analogues have 
been employed to develop a simultaneous, dual analyte assay in a single well for 
two important cardiovascular molecules, 6-keto-prostaglandin-FI-αand 
angiotensin II. A cysteine-free aequorin mutant was chemically conjugated to 6-
keto-prostaglandin-FI-αand genetically fused to angiotensin II. The 6-keto-
prostaglandin-FI-α aequorin complex was paired the native coelenterazine and 
showed a half-life of 0.5 s, while the angiotensin II-aequorin construct was paired 
with coelenterazine i and showed a half-life of 11.7 s.  Two distinct time intervals 
of 0-6 s and 6-25 s were then used to differentiate the signals and allow for 
simultaneous detection (100)  (See figure 10).  
Fluorescence in Analytical Chemistry 
Very similarly to bioluminescence, fluorescence has also been widely 
applied in analytical chemistry and aided in many scientific advances and 
breakthroughs.  The major difference between bioluminescence and 
fluorescence lies in the requirement for an excitation source.  While 
bioluminescence undergoes a chemical reaction to achieve an excited species, 
fluorescence relies on an outside light source to promote the chromophore to an 
elevated energy level.  The chromophore will then relax back to the ground state, 
releasing a photon of light corresponding to the energy difference.  Fluorescence 
offers some advantages over bioluminescence in that the intensity and duration 
of light emission can be adjusted by the excitation light.  Along with this however 
comes the need for the incorporation of an excitation source into the instrumental 
setup and also the possibility of high background fluorescence from unintended  
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Figure 10.  A visualization of the two kinetic windows used for the the duel 
analyte bioluminescent assay relying on half life difference for signal resolution.  
The signal windows were separated into a 0-6s window and a 6-25 window to 
allow the differientiation of the individual signals.  Reprinted with permission 
from:Rowe, L., Combs, K., Deo, S., Ensor, C., Daunert, S., Qu, X., 2008. 
Genetically Modified Semisynthetic Bioluminescent Photoprotein Variants: 
Simultaneous Dual-Analyte Assay in a Single Well Employing Time Resolution of 
Decay Kinetics. Analytical Chemistry 80(22), 8470-8476..  Copyright 2008 
American Chemical Society. 
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molecules, particular prevalent with physiological fluids, and the scattering of 
incident light.  Despite these limitations fluorescence has been and continues to 
allow for very versatile and sensitive detection systems.  Fluorescence is 
observed from a large population of sources including, but not limited to, small 
molecules, nanoparticles, amino acids, and proteins (101-103) (see figure 11).   
This diverse offering of fluorescent species catersto an increasing number of 
applications by allowing the selection of specific fluorescent molecules that can 
be optimized for the differing requirements of individual applications.  
Additionally,an assorted pallet of colors is also available enhancing the 
multiplexing capabilities (101, 104-105).  The fluorescent labeling applications 
are nurmerous but include functions such as immunoassays, molecular tagging, 
imaging, protein-protein interactions, and forensics to name a few (83, 103, 106).   
Fiber Optic Sensors 
Fiber optics are traditionally associated with their use in the 
telecommunications industry, but over the years fiber optics have become a 
popular choice for the transduction oflight in a plethora of biosensors and 
detection systems.  This wide spread used is merited by the many favorable 
characteristics they possess including chemical passiveness, small and 
customizable dimensions, immune to electromagnetic pickup, unaffected by 
harsh environments, and can carry light over vast distances (107).  Fiber optics 
are composed of a cylindrical silica core surrounded by a silica cladding.  The  
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Figure 11.  Different fluorescent proteins showing an example of the multiple 
colors avaible with fluorescent proteins.Reprinted by permission from Macmillan 
Publishers Ltd: [Nature Biotechnology] Shaner, N.C., Campbell, R.E., Steinbach, 
P.A., Giepmans, B.N., Palmer, A.E., Tsien, R.Y., 2004. Improved monomeric red, 
orange and yellow fluorescent proteins derived from Discosoma sp. red 
fluorescent protein. Nat Biotechnol 22(12), 1567-1572., copyright 2004. 
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refractive index of the core is slightly higher than that of the cladding which is 
what allows the total internal reflections and the ability to carry light extremely 
long distances with a minimal loss of intensity.  As mentioned, fiber optic sensors 
have been used in a variety of circumstanses, including luminescent, reflectance 
and absorption based systems.  Among the specific applications of fiber optic 
sensors include examples such as sensors for gases including hydrogen, 
oxygen, and hydrocarbons, pH, inorganic ions, glucose, DNA, and the 
employment with immunosensor and bacterial biosensing systems (108-116). 
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CHAPTER THREE 
 
SIMULTANTIOUS MULTIPLEXED CYTOKINE ANALYSIS VIA SEMI-
SYNTHETIC AEQUORIN FUSION PROTEINS 
 
INTRODUCTION 
 
Effective disease diagnosis depends largely on the knowledge of disease-
specific biomarkers.  In a majority of the cases, multiple biomarkers are 
necessary to accurately diagnose a disease.  In addition, the levels of biomarkers 
can be very low in physiological fluids adding to the complexity of the problem.  
Thus, the knowledge of biomarkers complemented with a rapid, highly sensitive, 
and multiplex detection method is one of the challenges in medicine. Movement 
towards the miniaturization of many systems in order to save time, money and 
resources has also lead to the requirement for not only more sensitive, but also 
more versatile labels.  Therefore, highly sensitive labels with multiplexing 
capabilities that can be employed in miniaturized systems are desired in clinical 
analysis. Luminescent proteins encompass many of these favorable 
characteristics and have the potential to unlock a vast new array of detection 
technologies. Bioluminescent proteins, including luciferases and photoproteins, 
have established themselves as vital components of the biosensing toolbox and 
have been used for an assortment of applications including gene expression, 
drug discovery, binding assays, in vivo indicators, and the study of protein-
protein interactions (5, 10, 117-121).  Bioluminescence offers distinct advantages 
over alternate detection methods, such as fluorescence or absorbance, including 
46 
 
lower detection limits due to essentially zero background signal in physiological 
fluids, no complications from an excitation source, simple instrumentation, the 
ability to be produced in vivo, biocompatibility, and lack of toxicity to living 
organisms (8, 122). Recent advances in instrumentation for the luminescence 
detection has also aided in the advancement of luminescent labels (8). However, 
unlike fluorescence-based detection, which can be performed at multiple 
emission wavelengths using different fluorophores or fluorescent proteins, 
bioluminescent proteins have lagged in this area. This issue has been tackled in 
a number of ways in current research that has expanded the utility of 
bioluminescent proteins in multiplex assays.  Recent progress in this area 
includes using two different naturally available luminescent proteins to achieve 
resolved signals (123-125), genetically engineered bioluminescent proteins 
exhibiting shifted emission profiles (96, 126), and genetically mutated 
photoproteins, specifically aequorin, differentiated through time resolution (100). 
The previous studies, although greatly advancing bioluminescent assays, are 
limited to two analytes.  These approaches have multiplexing capabilities but are 
limited by the availability of spectrally distinct or time-resolved mutants.  In this 
study, we have demonstrated that by combining both the spectrally distinct 
mutants and time resolved mutants we can extend the multiplexing capability of 
the bioluminescent protein, aequorin. To that end, the photoprotein aequorin has 
been employed for the simultaneous detection of three separate analytes in a 
single well, the signals of which will be differentiated through the use of three 
discrete time/wavelength windows (figure 12).   The three analytes of interest will 
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be conjugated to three different semi-sythetic aequorin proteins to create a 
competitive assay.  The aequorin labeled analytes will compete with free 
analytes in solution for a limited number of analyte binding sites.  Thus, as the 
concentration of free analyte increases the number of aequorin labeled analytes 
able to bind will decrease, decreasing the observered bioluminescent signal.   
Aequorin, native of the jellyfish Aequorea victoria, is a 22 kDa 
bioluminescent photoprotein with the active complex consisting of the 
apoaequorin, the imidazopyrazine chromophore coelenterazine contained in the 
protein’s hydrophobic core, and molecular oxygen.  The binding of calcium by 
aequorin triggers a conformational change in the protein leading to the oxidation 
of the coelenterazine to an excited state, which upon relaxation results in the 
emission of light with a λmax~ 469 nm (25, 127). Aequorin has been mutated both 
site-specifically and randomly to generate mutant aequorin proteins displaying 
altered emission maxima, emission decay half-lives, and thermostability(128-
132).  Additionally, introducing synthetic coelenterazine analogues creating 
“semi-synthetic” aequorin have also shown altered bioluminescent properties (97, 
133-139).  Thus, by combining both strategies of the mutated aequorin proteins 
and synthetic coelenterazines, an even greater diversity can be achieved (98).  
Herein we describe the simultaneous analysis of interleukins 1β (IL-1β), 6 (IL-6), 
and 8 (IL-8) in a single well through the genetic conjugation of the interleukins 
with semi-synthetic aequorin mutant proteins. These pro-inflammatory cytokines 
can serve as markers for the diagnosis and monitoring of a variety of diseases, 
including diabetes, prostate cancer, lupus, and hyperalgesia, but are present in  
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Figure 12.  A schematic of the simultaneous competitive assay for IL1β, IL6 and 
IL8.  The grey Y-shaped structures represent the anti-mouse IgG antibodies 
coated on the microtiter plates.  Anti-human IL1β, IL6, and IL8 antibodies are 
represented by the green, red, and blue Y-shaped structures respectively.  
Column A in the lower right hand corner represents the interleukin-aequorin 
fusion proteins while column B represents the free interleukin proteins.  IL1β is 
the orange cone and is attached to the Y82F aequorin mutant paired with ctz f 
(lime green sphere, detected in the 0-6 s and 515 nm window).  The blue 
ellipsoid represents IL6 and the red sphere Y82F aequorin mutant paired with ctz 
i (detected in the 6-25 s and 515 nm window).  The yellow triangle is IL8 and is 
fused with the F113W aequorin mutant (cyan sphere, detected in the 0-6 s and 
410 nm window). 
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very low concentrations in physiological fluids (140-145).  A rapid, sensitive, and 
multiplex assay systemswould be highly advantageous in the detection of 
biomarkers such as interleukins. 
EXPERIMENTAL PROCEDURES 
 
Reagents.  Disodium ethylenediaminetetraacetate (EDTA), Luria-Bertani (LB) 
agar, and LB broth were purchased from Fischer Scientific (Fair Lawn, NJ). 
Diethylaminoethyl  (DEAE) Fast Flow was obtained from GE Life Sciences.  
Poros 50 HQ was from AB Applied Biosystems (Foster City, CA). The Bradford 
protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA). 
Sodium dodecyl sulfate (SDS) was purchased from Curtin Mathesin Scientific 
(Houston, TX).  Plasmid mini-prep kits and gel extraction kits were obtained from 
Qiagen (Valencia, CA). T4 DNA ligase, alkaline phosphatase, and EcoRI,HindIII, 
and BamHI, restriction enzymes were purchased from Promega (Madison, WI). 
Pfu Ultra polymerase and Taq polymerase were from Stratagene (Ceder Creek, 
TX).  Tris(hydroxymethyl)amino methane (Tris) free base, ampicillin, Tween-20, 
sodium phosphate, sodium chloride, and bovine serum albumin (BSA) were 
purchased from Sigma Aldrich (St. Louis, MO). The cDNA clones of human IL-
1β, IL-6, and IL-8 were purchased from ATCC (Manassas, VA). The standard 
human IL-1β, IL-6, and IL-8 proteins, Top10, Top10F, JM101 chemical 
competent cells and human serum were obtained from Invitrogen (Carlsbad, CA).   
Human IL-1β/IL-1F2 monoclonal antibody, human IL-6 monoclonal antibody, and 
human CXCL8/ IL-8 monoclonal antibody were purchased from R&D systems 
(Minneapolis, MN).  Reacti-Bind goat anti-mouse IgG coated white 96-well plates 
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were from Pierce Biotechnology (St. Louis, MO).  All chemicals were reagent 
grade or better and all aqueous solutions were prepared using 16 MΩ deionized 
distilled water produced by a Milli-Q water purification system (Millipore, Bedford, 
MA). 
Apparatus.  Polymerase chain reactions (PCR) were performed using an 
Eppendorf Mastercycler Personal thermocycler (AG, Hamburg). DNA 
electrophoresis was performed using a FB105 Fischer Biotech Electrophorese 
Power Supply (Pittsburgh, PA) and the gels were visualized using a UV 
Transilluminator (UVP, Upland, CA). OD600 readings were taken using a 
Spectronic 21D UV-vis Spectrophotometer (Milton Roy, Ivy Land, PA). Bacteria 
employed for the expression of the interleukin-aequorin fusion proteins were 
incubated in a Fisher Scientific incubator orbital shaker and Fisher Scientific 
open air orbital shaker (Fair Lawn, NJ) and harvested by a Beckman J2-M1 
centrifuge (Palo Alto, CA).  All chromatographical purifications were performed 
on a BioCAD SPRINT perfusion chromatography system from Perceptive 
Biosciences (Framingham, MA).  Purity of the fusion proteins were verified by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using 
Invitrogen 10-20% Tris-glycine gels in an Invitrogen X Cell Sure Lock Mini Cell 
(Carlsbad, CA). Bioluminescence measurements were made on a Polarstar 
Optima luminometer from BMG Labtech (Cary, NC) and decay kinetics analyzed 
with GraphPad Prism 5.0 (San Diego, CA).  Emission spectra were taken on a 
custom made SpectroScan instrument from Sciencewares (Farmingham, MA). 
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Construction of Interleukin-Aequorin Mutant Fusion Proteins. Three different 
fusion protein constructs were developed for assaying interleukin 1 (IL-1), 
interleukin 6 (IL-6) and interleukin 8 (IL-8), simultaneously.  Previously, aequorin 
mutants when combined with synthetic coelenterazine analogs have been shown 
to exhibit altered emission spectra (98).  For this study, the genetic sequence 
coding for the Y82F and F113W aequorin mutants were utilized (135).  The 
interleukin coding sequences were genetically attached to the aequorin mutants 
of choice via overlap polymerase chain reaction (PCR) (figure 13).  Each fusion 
protein was also designed to contain a SGGGGS spacer sequence between 
theaequorin mutant and interleukin.  Aequorin mutant F113W was genetically 
attached to the 3´ end of IL-8 (IL8F113W) and aequorin mutant Y82F was 
genetically attached to the 3´ end of both IL-1β (IL1βY82F) and IL-6 (IL6Y82F).  
The specifics for each over lap PCR are as follows (See Table 1 for primer 
sequences):  
The IL-1β genetic coding sequence was amplified with the IL-1β forward 
primer which also introducedanEcoRI restriction site on the 5´ end, and the IL-1β 
reverse primer.  Meanwhile, the aequorin mutant Y82F coding sequence was 
amplified using the Aequorin forward primerand the BamHI aequorin reverse 
primer.  This amplification introduced a BamHI restriction site on the 3´ end of the 
aequorin gene sequence.  The two sequences were combined and then 
amplified with IL-1β forward and the BamHI aequorin reverse primer to yield the 
IL1βY82F coding sequence.  Similar genetic manipulations were performed with 
the IL-6 coding sequence as a template and using the IL-6 forward and reverse  
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Figure 13.  A schematic of the overlap PCR method used to create the IL-
aequorin fusion proteins.  Briefly, individual PCR reactions were performed to 
amplify the IL and aequorin gene separately while introducing a common linker 
region (represented by the yellow boxes).  The individual products were then 
combined in a single PCR reaction and amplified with the IL forward and 
aequorin reverse primers to produce the conjugated fusion protein gene.   
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Primer Sequence (5´-3´) 
Aequorin 
Forward 
TCTGGCGGTGGCGGTTCTGTGAAACTGACCAGCGACTTC 
Aequorin 
Reverse 
BamHI 
ATCGGATCCTTAGGGGACAGCTCCACCGTAGAGCTTTTCGGAAGCAGG
GTCCATGGTGTA 
 
Aequorin 
Reverse 
HindIII 
ATCAAGCTTTTAGGGGACAGCTCCACCGTAGAGCTTTTCGGAAGCAGGG
TCCATGGTGTA 
 
IL-1β 
Forward 
GAGGAATTCCAGATGCACCTGTACGATCA 
IL-1β 
Reverse 
TTTCACAGAACCGCCACCGCCAGAGGAAGACACAAATTGCATGGT 
IL-6 
Forward 
GAGGAATTCCAAACTCCTTCTCCACAAGC 
IL-6 
Reverse 
TTTCACAGAACCGCCACCGCCAGACATTTGCCGAAGAGCCCTCAG 
IL-8 
Forward 
GAGGAATTCCAAGTGCTAAAGAACTTAGA 
IL-8 
Reverse 
TTTCACAGAACCGCCACCGCCAGATGAGTTCTCAGCCCTCTTCAA 
 
Table 1.  The primer sequences used for the creation of the interleukin-aequorin 
fusion proteins. 
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primers.  This introduced an EcoRI restriction site on the 5´ end of IL-6.  The 
Y82F aequorin mutant was amplified similarly with aequorin forward primer and 
the HindIII aequorin reverse primer to introduce the HindIII restriction site on the 
3´ end of the aequorin gene.  The IL-6 and aequorin sequences were combined 
and amplified with the IL-6 forward and HindIII aequorin reverse primers to yield 
the IL6Y82F coding sequence.  Finally, the IL-8 forward and reverse primers 
were used in conjunction with the IL-8 coding sequence to introduce the EcoRI 
restriction site on the 5´ end. The aequorin forward and BamHI aequorin reverse 
primers were used to create a BamHI restriction site on the 3´ end of the F113W 
aequorin mutant.   This sequence was combined with the newly created IL-8 
coding sequence and the aequorin forward and IL-8 reverse primers were used 
to yield the IL8F113W coding sequence. The PCR reaction conditions were 95 
oC for 30 s, 55 oC for 30 s, followed by 72 oC for 1 min/1000 base pairs and 
repeated for 30 cycles. 
All of the fusion protein coding sequences were then inserted into an 
ompA containing pIN4 plasmid by using restriction digestions and subsequent 
ligations.  The DNA sequencing was performed by the Advanced Genetic 
Technologies Center at the University of Kentucky to confirm the gene for the 
fusion proteins. Then, the plasmids containing the gene for IL1βY82F and 
IL6Y82F were transformed into JM101 Escherichia coli cells and grown while 
shaking at 250 rpm at 37oC in 500 mL LB broth containing 100 µg/mL ampicillin 
overnight to an OD600 ~ 1.5.  The proteins were expressed in the periplasmic 
space, thus they were isolated from the cells through osmotic shock and then 
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purified through ion-exchange chromatography.  The proteins were loaded onto a 
DEAE Sepharose fast flow column in a 30 mM Tris/HCl pH 7.5, 2mM EDTA 
buffer.  A gradient was then run from 0-50 % of 30 mM Tris/HCl pH 7.5, 2 mM 
EDTA, 1 M NaCl over 10 column volumes.   Four fractions of one mL volume 
were collected and fractions containing the highest concentration of the fusion 
proteins, determined by SDS-PAGE and aequorin activity, were pooled.  The 
plasmid containing the IL8F113W gene was transformed into Top10F’ 
Escherichia coli cells and grown with shaking at 250 rpm at 4oC in 500 mL of LB 
broth containing 100 µg/mL ampicillin to an OD600 ~ 1.5.  The fusion protein was 
expressed in the periplasmic space and was isolated from the cells through 
osmotic shock followed by the purification through ion-exchange chromatography 
using the same procedure as above.  Protein concentration was determined by 
Bradford protein assay from Bio-Rad Laboratories (Hercules, CA).  All purified 
proteins were stored at 4oC until further use.   
Decay Half-Life of Interleukin-Aequorin Fusion Proteins.  The decay kinetics 
of each interleukin-aequorin fusion protein was examined with an array of 
coelenterazine analogues (ctz ntv, i, f, cp, hcp, fcp, n, fcp, h).  A three molar 
excess of each coelenterazine analog was added to aliquots of each of the three 
interleukin-aequorin fusion proteins and incubated 18 h at 4oC.  The fusion 
proteins were then diluted with 30 mM Tris/HCl, containing 2 mM EDTA, 150 mM 
NaCl, 1 mg/mL BSA pH 7.5 (buffer A) until the maximal bioluminescent 
intensities were between 50,000 and 500,000 relative light units (RLUs) when 
analyzed on the Polarstar Optima luminometer.  For the analysis, a volume of 10 
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µL of the coelenterazine bound fusion protein solution was added to the well of a 
microtiter plate and the bioluminescent light reaction was initiated by injecting 
100 µL of 30 mM Tris/HCl pH 7.5 buffer containing 100 mM CaCl2 (buffer B).  
The light intensity was then monitored for 25 s, with readings taken every 100 
ms.  The data was analyzed by GraphPad Prism 5.0 software using a non-linear, 
one phase exponential decay kinetics half-life equation.  
Bioluminescent Emission Spectra of Interleukin-Aequorin Fusion 
Proteins.The bioluminescent emission spectral profile was observed for each of 
the fusion proteins again with same array of coelenterazine analogues as used 
for the half-life study.  The emission spectra were collected on the SpectroScan, 
a custom made instrument based on the Thermo-Labsystems Luminoskan 
Ascent luminometer. The instrument is capable of recording the spectra of flash 
bioluminescence reactions in the range of 400-700 nm.  Again, a three molar 
excess of each coelenterazine was added to aliquots of each fusion protein and 
incubated for 18 h at 4oC.  A volume of 10 µL of the coelenterazine bound fusion 
protein solution was then added to a well on a 96 well microtiter plate.  A volume 
of 100 µL of buffer B was then injected in the well and the light was collected for 
6 s.   
Concentration Optimization of Fusion Proteins.  Each fusion protein was 
incubated for 18 h at 4oC with a three molar excess of a selected coelenterazine. 
The fusion protein IL1βY82F was incubated with coelenterazine f, IL6Y82F with 
coelenterazine i, and IL8F113W with coelenterazine cp.  The fusion proteins 
were then serially diluted with buffer A.  A volume of 50 µL of each protein of 
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selected concentration was added to a well on a 96 well microtiter plate, 100 µL 
of buffer B was injected into the well and bioluminescent signal was determined.  
The concentration optimization was performed on both the SpectroScan and 
Polarstar Optima.  For fusion proteins IL1βY82F and IL8F113W the SpectroScan 
CCD exposure time was set to 6 s and the Polarstar Optima also collected light 
for 6 s.  For IL6Y82F the SpectroScan CCD exposure time was set to 19 s with a 
6 s delay and the Polarstar Optima collected light from 6-25 s in a 25 s collection 
window.  The intensity at 452 nm for IL8F113W and 504 nm for IL1βY82F and 
IL6Y82F were plotted when analyzing SpectroScan data.   
Binder Dilution Plots for Fusion Proteins with Interleukin Specific Antibody.  
Monoclonal anti-human IL1β, anti-human IL6, and anti-human IL8 antibodies, 
isolated from mice, were purchased from R&D Systems (Minneapolis, MN).  
Binder dilution studies were performed in identical fashion for all antibodies with 
exception to the exposure times as noted below.  All antibodies were serially 
diluted in PBS buffer pH 7.4 containing 2 mM EDTA, 1 mg/mL BSA (buffer C) 
starting at an initial concentration of 10 µg/mL antibody. Anti-mouse IgG 
precoated 96 well microtiter plates were used for all experiments performed with 
antibodies.  Prior to incubation each well of the anti-mouse IgG precoated 96 well 
plate was washed three times with 100 µL of 30 mM Tris/HCl, pH 7.4 containing 
2 mM EDTA, 150 mM NaCl, 0.05% Tween-20 (buffer D).  Next, an aliquot of 50 
µL of each antibody concentration was added to the wells of the plate and 
allowed to incubate at 4oC with shaking at ~100 rpm for 2 h.  The antibody 
solution was removed from the wells and the wells were washed three times with 
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buffer D.  An aliquot of 50 µL of the corresponding fusion protein solution was 
then added to the wells and allowed to incubate with shaking at ~100 rpm, 4 oC 
for 1 h.  For the IL-1β antibody a concentration of 2.98 x 10-8 M IL1βY82F was 
used, 5.62 x 10-6 M concentration of IL6Y82F was employed with the IL6 
antibody, and 2.39 x 10-7 M of IL8F113W fusion protein was used with the IL-8 
antibody as determined from the concentration optimization studies of the fusion 
proteins.  The wells were then emptied and washed again three times with buffer 
D.  The microtiter plate was then loaded into the respective instrument and 100 
µL of buffer B was injected into each well and the emitted luminescence light was 
collected.  Binder dilutions plots were examined for both the SpectroScan and 
Polarstar Optima.  For fusion proteins IL1βY82F and IL8F113W the SpectroScan 
CCD exposure time was set to 6 s and the Polarstar Optima collected light for 6 s 
also.  For the fusion protein IL6Y82F the SpectroScan CCD exposure time was 
set to 19 s with a 6 s delay and the Polarstar Optima collected light from 6-25 s in 
a 25 s collection window.  The intensity at 452 nm for IL8F113W and 504 nm for 
IL1βY82F and IL6Y82F were plotted when analyzing SpectroScan data.   
Individual Interleukin Dose-Response Plots.  Anti-mouse IgG coated plates 
were employed for all experiments.  Before use each well was washed three 
times with 200 µL of buffer D.  An aliquot of 50 µL of the respective antibody at 
the specified concentration (diluted with buffer C) was added to each well and 
allowed to incubate with shaking at ~100 rpm at 4 oC for 1.5 h.  The antibody 
concentrations used were as follows: 0.005 µg/mL for anti-human IL1β and anti-
human IL6 and 0.05 µg/mL for anti-human IL6.  The antibody solution from each 
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well was removed and again washed three times with 200 µL of buffer D.  Human 
interleukin standards (Invitrogen, Carlsbad, CA) were serially diluted in buffer C 
and 100 µL of the varied concentrations (in triplicate) were added to the wells 
and allowed to incubate with shaking at ~100 rpm at 4oC for 1.5 h.  The wells 
were emptied and washed with 200 µL of buffer D and 50 µL of the 
corresponding interleukin-aequorin fusion protein was added to each well and 
allowed to incubate with shaking at ~100 rpm at 4oC for 1 h.  Fusion protein 
concentrations used in the study were as follows: IL1βY82F with coelenterazine 
f- 2.98x10-8 M, IL6Y82F with coelenterazine i- 5.62 x 10-6 M, and IL8F113W with 
coelenterazine cp- 2.39 x 10-7 M. The wells were emptied and washed with 200 
µL of buffer D.  Then, an aliquot of 100 µL of buffer B was added to each well, 
and the bioluminescent intensity was measured using both the SpectroScan and 
Polarstar Optima.  For the SpectroScan the CCD exposure time was set to 6 s 
for the wells containing IL1βY82F and IL8F113W and 19 s with a 6 s delay for 
IL6Y82F.  For the Polarstar Optima dual luminescence emission detection with 
two kinetic windows was utilized.  Channel A contained a 410 nm filter and 
channel B housed a 515 nm filter (both of BMG Labtech (Cary, NC).  The first 
kinetic window consisted of the 0-6s time frame after addition of the buffer B and 
the second window was 6-25s.    
Simultaneous Multiplexed Interleukin Dose-Response Plots in Buffer and 
Human Serum.  For the dose-response plots in buffer, pre-coated anti-mouse 
IgG plates were washed three times with 200 µL of buffer D.  To each well, an 
aliquot of 50 µL of each of the anti-human interleukin antibodies in the same 
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concentrations as used for the individual dose response plots listed above was 
added and allowed to incubate for 1.5 h with shaking at ~100 rpm at 4 oC.  The 
antibody solution was removed and the wells were washed three times with 300 
µL of buffer D.  An aliquot of 100 µL of each interleukin standard solution was 
then added to the wells.  For each of the interleukins the response was examined 
in a dose-dependent manner while the concentration of the other two interleukins 
was held constant at 100 pg/mL.  The interleukin solutions were allowed to 
incubate with shaking at ~100 rpm at 4 oC for 1.5 h.  The solutions were then 
removed from the wells and the wells were washed three times with 300 µL of 
buffer D.  An aliquot of 50 µL of each interleukin-aequorin fusion protein was then 
added to the wells and allowed to incubate for 1 h with shaking at ~100 rpm at 4 
oC.   The wells were then drained and washed three times with 300 µL of buffer 
D.  
The same procedure was followed for the dose-response plot generated 
using human serum with the exception of the additions of the standard solutions.  
In order to establish a calibration plot, aliquots of human serum (Invitrogen, 
Carlsbad, CA) were spiked with the cytokines of interest to the final desired 
concentration. One of the cytokines was added in the varying concentrations 
while the other two were held constant at 100 pg/mL.  A total volume of 200 μL of 
the human serum with the desired interleukin concentrations was added to each 
well and allowed to incubate with shaking at ~100 rpm at 4 oC for 1.5 h.  The 
bioluminescent response was then observed on the Polarstar Optima after the 
addition of 150 µL of buffer B to each well.  Dual luminescence, with the 410 nm 
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and 515 nm filters, was again employed in the two distinct kinetic windows of 0-
6s and 6-25 s after the injections of buffer B into the well.  All measurements 
were performed in triplicate with the mean value plotted.       
 
RESULTS AND DISCUSSION 
Three pro-inflammatory cytokines (IL-1β, IL-6 and IL-8) were chosen as 
biomarker candidates for the proof of principle multiplex detection system based 
on the fact that they are present in low concentrations in physiological fluids and 
their simultaneous detection would be beneficial in the diagnosis of a number of 
diseases (140-145). The current move towards miniaturization of many detection 
systems combined with low analyte concentrations in physiological samples 
requires extremely sensitive labels.   Multiplexing of assay systems would also 
prove advantageous and greatly improve the analytical and diagnostic value of 
the assay systems.  Bioluminescent labels can provide us with the required 
miniaturization potential and sensitivity however, up to now there have been few 
examples of their use in multiplex assays.  Previously, semi-synthetic aequorin 
was used in a dual analyte assay based on time resolution (100), while obelin 
mutants and luciferases were applied in dual-color assays (96, 126).  By 
combining both time and wavelength resolution the bioluminescent multiplexing 
capabilities can be expanded even further in bioanalytical and medical 
applications.    
The selection of semi-synthetic aequorins was centered off our previous 
work that studied the effect of genetic mutations and synthetic coelenterazines 
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on the observed emission maxima and decay kinetics of the semi-synthetic 
aequorins (98).  Based on this work,we selected aequorin mutants Y82F and 
F113W as labels for the development of the current multiplex assay.  This 
decision was based on the fact that these mutants would allow for maximal 
spectral and time resolution while maintaining ample bioluminescence activity.  
The genes for the interleukin proteins were fused to the genes of the aequorin 
mutants through an overlap PCR procedure and ligated into the pIN4 expression 
plasmid.  Optimal expression of the IL1βY82F and IL6Y82F fusion proteins was 
achieved by introducing the plasmids into the Escherichia coli JM101 strain, 
while the IL8F113W was expressed in the TOP10F´Escherichia coli strain.  Purity 
of the proteins was verified by SDS-PAGE.  In addition to size, the aequorin 
bioluminescence activity and the visualization in a Western blot with the 
respective anti-interleukin antibodies confirmed that the proteins not only 
contained both the aequorin and interleukin portions, but also would bind as 
required with the antibodies employed in the assays.   
Previous studies have shown that certain genetic mutations and different 
synthetic coelenterazines can result in altered emission characteristics of 
aequorin (98).  To evaluate the effect of genetically attached interleukinson the 
bioluminescence emission of aequorin, each fusion protein was investigated with 
an array of synthetic coelenterazines with respect to the emission maxima and 
decay kinetics.  A broad range of half lives was observed ranging from 0.10 s up 
to 14.2 s (Table 2b).  In addition the emission maxima exhibited by the fusion 
proteins with same array of coelenterazines were also investigated.  The  
63 
 
 
A. IL1βY82F IL6Y82F IL8F113W 
Coelenterazine Emission 
Maximum (nm) 
Emission 
Maximum (nm) 
Emission 
Maximum (nm) 
ntv 501 503 475 
i 509 507 484 
f 506 504 480 
ip 480 481 453 
hcp 480 483 453 
h 501 501 470 
cp 476 478 452 
fcp 490 486 470 
n 512 504 480 
 
B. IL1βY82F IL6Y82F IL8F113W 
Coelenterazine Half-life (s) Half-life (s) Half-life (s) 
ntv 1.10 0.87 0.66 
i 14.14 14.21 11.65 
f 0.53 0.52 0.56 
ip 0.39 0.39 0.59 
hcp 0.10 0.10 0.12 
h 0.20 0.19 0.19 
cp 0.17 0.15 0.16 
fcp 0.24 0.21 0.34 
n 2.83 2.72 0.90 
 
Table 2.  A. The monitoring of the maximal emission wavelength of the different 
interleukin-aequorin fusion proteins with an array of synthetic coelenterazines. All 
measurements were performed in triplicate with the mean response used for 
analysis.  B. The measured emission half-lives of the interleukin-aequorin fusion 
proteins with the same array of synthetic coelenterazines.  All measurements 
were performed in triplicate with the mean response used for analysis.   
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emission profile through the entire spectra of the visible region was recorded by a 
liquid cooled CCD camera and the wavelength maximum was determined 
corresponding to the maximal bioluminescent emission intensity.  A maximal 
wavelength separation of 57 nm was obtained ranging from 452 nm to 509 nm 
for the IL8F113W mutant and IL1βY82F mutant, respectively (Table 2a).  Based 
on these results, semi-synthetic aequorin mutants with coelenterazines cp, f, and 
i were selected for theestablishment of three distinct time/wavelength windows in 
which the simultaneous discrimination of the three separate bioluminescent 
signals can be achieved.  The fusion protein IL1βY82F was paired with 
coelenterazine f, IL6Y82F with coelenterazine i and IL8F113W with 
coelenterazine cp.  This would allow IL-1β to be detected in the 0-6 s interval 
using a 515 nm filter.  IL-6 can be detected in the 6-25 sinterval also with the 515 
nm filter, and IL-8 can be distinguished in the 0-6 s interval using a 410 nm filter.  
Wavelength resolution between the IL1βY82F and IL8F113Wsignals was 
achieved using the band pass filters of 410 nm and 515 nm allowing for 
thedetection of both IL-1β and IL-8 in the 0-6 s kinetic window (figure 14a). After 
6 s the only signal left is from the IL6Y82F emission, thus in the 6-25 s kinetic 
window with the 515 nm filter IL-6 can be detected as demonstrated in figure 
14b.  
Serial dilutions were made of each interleukin-aequorin fusion protein to 
determine the optimal concentration for use with the assay (figure 15). 
Concentrations of 2.98x10-8 M for IL1βY82F with coelenterazine f, 5.62 x 10-6 M  
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Figure 14. A. The emission spectra profiles of the three interleukin-aequorin 
fusion proteins with the respective ctz’s combinations selected for the study.  All 
measurements were performed in triplicate with the mean response plotted and 
normalized with the maximal intensity assigned the value of 1.  B. The emission 
decay kinetics of the three fusion protein/ ctz combinations.  All points are the 
mean of three replicates.  The response was again normalized with respect to 
the maximal intensity which was made equal to 1. 
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Figure 15.  Concentration optimization of all three IL fusion proteins.  All points 
are the average of triplicate measurements ± one standard deviation.  Error bars 
not visible are concealed by the points.   
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for IL6Y82F with coelenterazine i, and 2.39 x 10-7 M for IL8F113W with 
coelenterazine cp were selected for the studies based on the fact that these 
concentrations allowed for significant amount of signal over the background while 
minimizing the amount of reagents used.  Additionally, binder-dilution studies 
with the respective anti-human interleukin antibodies were performed to optimize 
the antibody concentration (figure 16).  For that, anti-mouse IgG coated plates 
were utilized to allow for optimal orientation of the anti-interleukin antibodies (all 
mouse IgG) in the wells.   An antibody concentration of 0.005 µg/mL for the anti-
human IL-1β and IL-8 antibodies and a concentration of 0.05 µg/mL for the anti-
human IL-6 antibody were found to be most favorable in terms of the detection 
range of the assay.Initially, the dose response-plots for the desired interleukins 
were executed individually to allow for optimization.  Each of the interleukins 
were able to be detected through the physiologically elevated relevant 
concentration range (~10 pg- 1000 pg) (146-148) with detection limits of 0.1 
pg/mL for IL-1β and IL-8 and 1.0 ng/mL for IL-6 (figure 17).  Each interleukin was 
then assayed with all of the interleukins present in a single well (figure 18).  A 
similar procedure was followed as for the individual dose-response plots with 
exception that all three of the antibodies, standards, and fusion proteins were 
added to each well.  Two of the interleukin concentrations were held constant 
while the third wasincreased through the desired range to demonstrate that the 
observed change was only affected by the expected fusion protein signal. The 
concentrations of the two interleukins were held constant at a typical elevated 
concentration of 100 pg/mL.  Even though the fixed concentration is high, it does  
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Figure 16.  Binder dillution plots for all three antibodies.  All points are the 
average of triplicate measurements ± one standard deviation.  Error bars now 
visible are concealed by the points.   
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Figure 17.  Individual dose response plots of the three analytes of interest in a 
buffered solution.  All points are the mean of three measurements ± one standard 
deviation.  Error bars that are not visible are obstructed by the points. 
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Figure 18.  Simultaneous dose-response plots of all three analytes in a single 
well with a buffered solution.  All three time/wavelength windows are plotted.  The 
response of the IL-1β in the 515 nm, 0-6s window has been corrected for the 
effect of the IL6Y82F signal. All points are the mean of three measurements ± 
one standard deviation.  Error bars that are not visible are obstructed by the 
point. 
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not interfere with the assay for the target interleukin. As expected, the response 
for interleukin 6 could be seen throughout both of the long and short kinetic 
windows.  The IL6Y82F protein with coelenterazine i has a long half-life, thus the 
signal is not only present in the 6-25 s kinetic window but also in the 0-6 s.To 
resolve this issue the long decay component can be subtracted from the short 
decay component by the use of a signal deconvolution algorithm as described 
previously (100).Dose-response plots for the simultaneous detection of three 
interleukins showed a similar profile as the individual interleukins and was 
capable of detecting the analytes in the relevant concentration range with 
detection limits of 0.3 pg/mL for IL-1β and IL-8 and 0.3 ng/mL for IL-6. The 
response from fusion proteins with the fixed interleukin concentrations did not 
interfere with the target signal outside of the expected presence of the IL-6Y82F 
aequorin in both the long and short time intervals.  Additionally, the multiplex 
assay was performed using human serum as the sample matrix.  Being able to 
perform the assays directly in physiological fluids will eliminate sample 
preparation steps, reduce assay time, and thus allow for quicker disease 
diagnosis.  The system again showed high sensitivity and specificity, detecting 
the desired analyte with a four order of magnitude dynamic range that 
encompass the physiological levels of interleukins.  The detection limits of 3 
pg/mL for IL-8, 30 pg/mL for IL-1β and 0.3 ng/mL for IL-6 (figure 19) were 
obtained.   
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Figure 19. Simultaneous dose response plots of all three analytes in human 
serum in a single well.  The response in the specific time/wavelength window of 
interest for each interleukin is plotted separately for ease of viewing. The 
response of the IL-1β in the 515 nm, 0-6s window has been corrected for the 
effect of the IL6Y82F signal. All points are the mean of three measurements ± 
one standard deviation.  Error bars that are not visible are obstructed by the 
point. 
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 Currently there are several other methods for the quantification of human 
interleukins including ELISA, flow cytometry, and meso scale base systems.  
Each system offers advantages and disadvantages, which can vary by the 
individual experimental needs.  All require specialized equipment and space for 
the required instruments.  The aequorin based competive assay offers similar 
detection limits as the alternative methods, corresponding with the physiologically 
relevant concentration ranges.  Additionally, the unique ability of aequorin to be 
detected at extremely low levels with minimal background allows the potential for 
aequorin labels to be incorporated with miniaturized devices.  Miniaturized 
devices offer greater prospective for point of care diagnostics and field 
applications where a small, portable device is required.   
CONCLUSIONS 
Bioluminescent labels capable of multiplex detection have the opportunity 
to be a key element for the advancement of detection systems as the move 
towards miniaturization progresses, requiring more sensitive, quick, and cost 
efficient labels. Herein the multiplexed detection of three analytes is presented. 
The system was able to respond quickly and efficiently in a dose-dependent 
manner over several orders of magnitude, including the physiological and 
elevated range for the specific interleukinprotein biomarkers of interest. 
Previously, dual-analyte bioluminescent assays have been reported either based 
on spectral or time resolved bioluminescentproteins (96, 100, 123-126). 
However, in this study we have demonstrated that a combination of both time 
and wavelength resolved aequorin mutants impart enhanced multiplexing 
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capabilities for the development of a bioluminescence-based detection system.  
In addition,both spectral and time resolved aequorin mutants need a calcium 
solution to trigger bioluminescence, unlike in the case of dual luciferase system 
where the bioluminescence is triggered using different reagents.  This, in addition 
to the fact that band pass filters are implemented for wavelength discrimination, 
allows for simplifying instrumentation requirements and maintaining cost 
effectiveness.  The high sensitivity of aequorin also allows for easy quantification 
even in small volumes and the microtiter plate format aids in high-throughput 
screening.  Lab-on-a-chip and lab-on-a-CD set-ups also offer compatible 
platforms with which a label of this type could be utilized for the development of a 
more versatile detection system.  As the library of semi-synthetic aequorins 
expands introducing a variety of emission maxima and decay kinetics, this 
combination of time and wavelength resolution could offer a novel pathway for 
the development of multiplex assays and expand the possibilities for the 
advancement of diagnostic and detection systems.  
 
 
 
 
 
 
 
 
Copyright © Daniel F. Scott 2011 
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CHAPTER FOUR 
 
GENETICALLY ENHANCED SEMI-SYNTHETIC AEQUORIN VARIANT WITH 
IMPROVED DETECTION AND IMAGING CAPABILITIES 
 
INTRODUCTION 
Driven by its unique and attractive properties, bioluminescence continues 
to emerge as an alternative method of detection in many clinical and diagnostic 
applications.  Coinciding with continuing improvements in instrumentation, 
bioluminescence has found utility in a variety of applications including assay 
development, investigation into gene expression, whole cell sensing, and 
intracellular analysis to name a few (5, 10, 117-120).  Even more recently, 
bioluminescent proteins have started to surface as an imaging agent.  Typically 
the imaging is achieved using genetically engineered cells to express the 
bioluminescent reporter, of which the bioluminescent emission can be used to 
analyze physio-pathological processes, disease progression, bacterial infection, 
and intracellular interaction (149-153).   The bioluminescence signal is generated 
through a chemical reaction, which eliminates the need for an external light 
source and thus, avoids any background signal.  This property is very useful in 
imaging applications compared to the imaging using green fluorescent protein, 
which suffers from high cellular autofluorescence background.  There are a few 
luciferase enzymes that have been traditionally employed for bioluminescent 
imaging studies.  The photoprotein aequorin has not been widely used in such 
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studies, however, due its flash type kinetics (~1 s half-life) and the extremely 
slow turnover rate once the bioluminescence flash has occurred.  Herein we 
describe a genetically enhanced aequorin mutant that shows improved detection 
and imaging capabilities. Specifically, the Y82F mutant aequorin that displays a 
longer wavelength and increased half-life when paired with the coelenterazine i 
was employed as a label for the detection and imaging applications.  We 
demonstrate the feasibility of implementing the protein aequorin as an 
immunolabel, able to detect a desired antigen down to the attomole range and as 
few as three target cells of interest.   
Occurring natively in the jellyfish Aequorea victoria, the photoprotein 
aequorin consists of apo-aequorin (22 kDa) and the imidazopyrazine 
chromophore coelenterazine contained in the protein’s hydrophobic core.  
Aequorin binds calcium, which induces a conformational change in the protein 
that, in the presence of molecular oxygen, allows the oxidation of the 
coelenterazine to an excited coelenteramide. Relaxation of the excited state 
coelenteramide results in the emission of a photon of light with a λmax~ 469 nm 
(25, 127).  The spent coelenteramide is still bound by the photoprotein and is 
slow to be released; thus, as long as excess coelenterazine is present in the 
initial solution the intensity of the emitted light will be directly proportional to the 
moles of photoprotein in the sample (25).  Bioluminescent proteins, such as 
aequorin, havebeen shown to have great potential as a label in analytical 
applications, demonstrating very efficient quantum yields. In addition, the light 
emission is a direct result of a chemical reaction, eliminating the need for an 
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outside excitation source, which dramatically reduces nonspecific signal and 
autofluorescence from the sample solution, allowing extremely high sensitivity.  
Aequorin has recently been shown to yield sensitivity as an immunolabel similar 
to alkaline phosphatase and horseradish peroxidase (154).  Furthermore, 
extensive random and site-directed mutagenesis have been performed on 
aequorin, which in combination with the use of synthetic coelenterazines, has 
greatly expanded the spectral diversity of aequorin’s bioluminescence (97-98, 
128-139).   
The CD33 protein and anti-CD33 antibody were chosen as a model 
system to assess the engineered aequorin’s analytical potential in addition to 
improving its imaging capabilities (figure 20).  CD33 is a 67 kDa glycoprotein      
expressed uniquely on the surface of 80-90% of acute myeloid leukemia (AML) 
cells (155-156).  CD33 has been used as a target for anti-cancer drugs.  For 
example, Mylotarg, which couples the cytotoxic drug calicheamicin to an anti-
CD33 antibody, has been shown effective for the treatment of AML patients 
(157).  Additionally, cell free circulating CD33 has also been shown to be 
significantly higher in patients with AML and may also be important for clinical 
applications (158).  It was demonstrated that by adding a unique cysteine into the 
sequence of the Y82F aequorin mutant, the protein can be employed as a 
sensitive immuno-label, allowing the detection of both free and surface attached 
CD33 at very low levels.  Additionally, an effort towards the ability to use 
aequorin in novel imaging applications is also presented.   
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Figure 20.  A schematic of the developed system for the detection of AML cells.  
CD33 (blue) are expressed on the surface of AML cells (red).  CD33 is 
recognized by the anti-CD33 antibody (grey) which is conjugated to C5Y82F 
aequorin (small spheres on the grey structure).  Upon the addition of Ca2+ the 
aequorin will emit light with the increasing intensity corresponding to an 
increased number of bound aequorin labeled antibodies.   
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EXPERIMENTAL PROCEDURES 
Reagents.  Disodium ethylenediaminetetraacetate (EDTA), Luria-Bertani (LB) 
Agar, LB Broth and Amicon Ultra 4 spin filters were purchased from Fischer 
Scientific (Fair Lawn, NJ). Diethylaminoethyl (DEAE) Fast Flow was obtained 
from GE Life Sciences.  Poros 50 HQ was purchased from AB Applied 
Biosystems (Foster City, CA). The Bradford protein assay kit was from Bio-Rad 
Laboratories, Inc. (Hercules, CA). Sodium Dodecyl Sulfate (SDS) was purchased 
from Curtin Mathesin Scientific, Inc. (Houston, TX).  Plasmid mini-prep kits and 
gel extraction kits were obtained from Qiagen (Valencia, CA). T4 DNA ligase, 
alkaline phosphatase, and EcoRI and HindIII restriction enzymes were 
purchased from Promega (Madison, WI). Pfu Ultra polymerase and Taq 
polymerase were obtained from Stratagene (Ceder Creek, TX).  
Tris(hydroxymethyl)amino methane (Tris) free base, HEPES, ampicillin, sodium 
phosphate, sodium chloride, potassium chloride, magnesium chloride potassium 
phosphate and bovine serum albumin (BSA) were purchased from Sigma Aldrich 
(St. Louis, MO). Top10 chemical competent cells were from Invitrogen (Carlsbad, 
CA).  CD33 monoclonal antibody and recombinant human CD33 were purchased 
from R&D systems (Minneapolis, MN).  CD33 polyclonal antibody was obtained 
from Novus Biologicals (Littleton, CO).  Sulfo-LC-SPDP, DTT (Dithiothreitol), 
Zebra Spin desalting columns, Reacti-Bind goat anti-mouse IgG coated white 96-
well plates and Reacti-Bind goat anti-rabbit IgG coated white 96-well plates were 
purchased from Pierce Biotechnology (St. Louis, MO).  HL-60 cells, Iscove's 
Modified Dulbecco's Medium, and Fetal Bovine Serumwere purchased from 
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American Type Culture Collection (ATCC)(Manassas, VA).  All chemicals were 
reagent grade or better and all aqueous solutions were prepared using 16 MΩ 
deionized distilled water produced by a Milli-Q water purification system 
(Millipore, Bedford, MA). 
Apparatus.  Polymerase chain reactions (PCR) were performed using an 
Eppendorf Mastercycler Personal thermocycler (AG, Hamburg). DNA 
electrophoresis was performed using a FB105 Fischer Biotech Electrophorese 
Power Supply (Pittsburgh, PA) and the gels were visualized using a UV 
Transilluminator (UVP, Upland, CA). OD600 readings were taken using a 
Spectronic 21D UV-Vis Spectrophotometer (Milton Roy, Ivy Land, PA). Bacteria 
employed for the expression of the aequorin protein were incubated in a Fisher 
Scientific incubating orbital shaker and Fisher Scientific open air orbital shaker 
(Fair Lawn, NJ) and harvested by a Beckman J2-M1 centrifuge (Palo Alto, CA).  
All chromatographical purifications were performed on a BioCAD SPRINT 
perfusion chromatography system from PerSeptive Biosciences (Framingham, 
MA).  Purity of the fusion proteins were verified by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) using Invitrogen 10-20% Tris-
glycine gels in an Invitrogen X Cell Sure Lock Mini Cell (Carlsbad, CA). 
Bioluminescence measurements were made on a Polarstar Optima luminometer 
from BMG Labtech (Cary, NC) and decay kinetics analyzed with GraphPad Prism 
5.0 (San Diego, CA).  Emission spectra were taken on a custom made 
SpectroScan instrument from Sciencewares (Farmingham, MA).  Tissue cultures 
were maintained in a Thermo Scientific (Waltham, MA) NAPCO series 8000 DH 
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CO2 Incubator at 37 
oC, 5% CO2 and cellular concentrations were determined via 
Nexcelom Biosciences (Lawrence, MA) Cellometer Vision cell counter.  Imaging 
experiments were performed on an Andor iXon EMCCD camera (Andor 
Technology, Belfast, Ireland) attached to a Nikon E600FN microscope and data 
acquisition and analysis were performed using Imaging Workbench 5.0 (Indec 
BioSystems, Santa Clara, CA, USA). 
Construction of Genetically Modified Aequorin.The Y82F aequorin mutant 
developed previously in our lab (98) served as a base for the studies.  To allow 
for site-specific conjugation of the protein to the CD33 antibody, the PCR was 
used to produce a Y82F mutant coding for a unique cysteine at amino acid 
position 5.  The cysteine free Y82F aequorin coding sequence (98) was used as 
the template in the PCR and amplified with the following primers to produce the 
C5Y82F aequorin mutant. 
Forward Primer: 
GTGGAATTCCAATGGTGAAACTGACCTGCGACTTCGACAACCCAAGATGGA 
Reverse Primer:  
CACAAGCTTTTAGGGGACAGCTCCACCG 
The position introducing the unique cysteine is highlighted in red letters.  The 
forward and reverse primers also introduced EcoRI and HindIII restriction sites.  
The PCR product was then ligated into the EcoRI – HindIII sites of the ompA 
containing pIN4 plasmid. The plasmid containing the gene for C5Y82F aequorin 
was used to transform Top10 E. coli cells. The correct DNA sequence of the 
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mutant aequorin gene was confirmed by the Advanced Genetic Technologies 
Center at the University of Kentucky.  
Expression and Purification of Aequorin.E. coli cells containing the plasmid 
encoding for C5Y82F were grown in 500 mL Luria Bertani (LB) broth containing 
100 µg/mL ampicillin while shaking at 250 rpm at 37 oC overnight to an OD600 ~ 
1.5.  The protein was expressed without any induction being required and was 
released from the cells into the culture media.  The cells were then pelleted by 
centrifugation at 12,000 x g for 15 min and the supernatant (medium) containing 
the aequorin was saved.  The C5Y82F aequorin was acid precipitated by adding 
glacial acetic acid dropwise to the medium to a final pH of 4.2 and incubating at 4 
oC for 2 h.  The solution was then centrifuged at 12,000 x g for 20 min to isolate 
the precipitated protein. The protein pellet was resuspended in 30 mM Tris/HCl 
pH 7.5 buffercontaining 2mM EDTA. The protein was centrifuged at 12,000 x g 
for 15 min to remove any particulate matter and then purified by ion-exchange 
chromatography using a BioCAD Sprint system.  The protein was loaded onto a 
DEAE Sepharose Fast Flow column (20 mL column volume) equilibrated with 30 
mM Tris/HCl pH 7.5 buffer containing 2mM EDTA.  A gradient was then run from 
0-50 % of 30 mM Tris/HCl pH 7.5, 2 mM EDTA, 1 M NaCl over 10 column 
volumes.   Four mL fractions were collected and fractions containing the highest 
concentration of the aequorin, as determined by SDS-PAGE and aequorin 
activity, were pooled.  All purified proteins were stored at 4 oC until use.    
Chemical conjugation of C5Y82F aequorin to CD33 monoclonal 
antibody.The C5Y82F aequorin mutant was chemically conjugated to the CD33 
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monoclonal antibody through the use of the heterobifunctional cross-linking 
molecule Sulfo-LC-SPDP.  Sulfo-LC-SPDP is capable of conjugating two proteins 
through the reaction of amine groups of one protein and sulfhydryl residues of 
the other.  First 20 µL of 20 mM Sulfo-LC-SPDP was added to 100 µg of the 
CD33 monoclonal antibody and allowed to incubate for 4 h at 4 oC to react the 
NHS ester end of the molecule with the amine groups of the antibody.  A 10 mM 
DTT solution was added to the C5Y82F aequorin solution and allowed to 
incubate at 4 oC for 4 h.  To remove unreacted Sulfo-LC-SPDP and DTT both 
solutions were passed through Zebra Spin Desalting Columns (Pierce 
Biotechnology) pre-equilibrated with phosphate buffered saline (PBS) pH 7.2, 2 
mM EDTA (buffer A).  Immediately after the buffer exchange a 10 times mole 
excess of the C5Y82F aequorin was added to Sulfo-LC-SPDP activated CD33 
monoclonal antibody solution and incubated for 16 h at 4 oC to react the 2-
pyridyldithiol group on the other end of Sulfo-LC-SPDP with the reduced 
sulfhydryl group on C5Y82F aequorin.  Unconjugated C5Y82F aequorin was 
removed by centrifugation with an Amicon Ultra 4 spin filter (MWCO 50K). 
Decay Half-Life of Free and Conjugated Mutant Aequorin. The decay kinetics 
of both the free and conjugated C5Y82F aequroin were examined with an array 
of coelenterazine analogues.  A three molar excess of each coelenterazine 
analog was added to aliquots of both forms of the protein and incubated for 18 h 
at 4 oC.  The fusion proteins were then diluted with buffer A until the maximal 
bioluminescent intensities were below 500,000 relative light units (RLUs) when 
analyzed on the Polarstar Optima luminometer.  A volume of 10 µL of the 
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coelenterazine bound protein solution was added to the well of a microtiter plate 
and the bioluminescent light reaction was initiated by injecting 100 µL of 100 mM 
CaCl2, 30 mM Tris/HCl pH 7.5 (buffer B) into the well.  For all of the 
coelenterazines except coelenterazine i the light emission was monitored for 25 
s, with readings taken every 100 ms.  For coelenterazine i, the light emission was 
monitored for 50 s with a reading taken every 200 ms.  All measurements were 
taken in triplicate and the mean of the three measurements used for the half-life 
analysis.  The data was analyzed by GraphPad Prism 5.0 software using a non-
linear, one phase exponential decay kinetics half-life equation. The analysis was 
initiated at the time interval displaying the maximal bioluminescent intensity as to 
only evaluate the decay of the light emission.   
Bioluminescent Emission Spectra of Free and Conjugated Mutant 
Aequorin.The bioluminescent emission spectra profile was observed for both the 
free and conjugated aequorin with same array of coelenterazine analogues as 
used for the half-life study.  The emission spectra were collected on the 
SpectroScan, a custom made instrument based on the Thermo-Labsystems 
Luminoskan Ascent luminometer. The instrument is capable of recording the 
spectra from flash reactions through the visible region of 400-700 nm.  Again, a 
three molar excess of each coelenterazine was added to aliquots of each protein 
form and incubated for 18 h at 4 oC.  A volume of 30 µL of the coelenterazine 
bound fusion protein solution was then added to a well on a 96 well microtiter 
plate.  A volume of 100 µL of buffer B was then added to the well and the light 
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was collected for 6 s.  All measurements were taken in triplicate and the mean 
used for emission maximum determination.   
CD33 Dose Response.  A dose response plot for free CD33 was first developed 
using C5Y82F aequorin as a label.  Goat anti-rabbit IgG coated microplates 
(Pierce Biotechnology) were used for the study.  The wells of the plate were 
initially washed three times with 150 µL of buffer A.  A volume of 100 µL of 1 
µg/mL rabbit anti-human CD33 polyclonal antibody was added to each well and 
allowed to incubate with shaking for 2 h at 4oC.  The antibody solution was 
removed and the wells were then washed with 150 µL of buffer A.  Next, 100 µL 
of each CD33 concentration was added to the wells and allowed to incubate with 
shaking at 4 oC for 2 h.  The wells were emptied and washed three times with 
buffer A.  A volume of 100 µL of the mouse anti-human CD33 monoclonal 
antibody conjugated to C5Y82F aequorin was added to the wells and allowed to 
incubate with shaking at 4 oC for 1 h.  The aequorin conjugated antibody solution 
was removed and the microtiter plate was washed three times with buffer A to 
remove any unbound protein.  Next, 100 µL of buffer B was added to each well 
and the bioluminescence intensity was measured for 4 s on the Polarstar Optima.  
All measurements were taken in triplicate with the mean of the set plotted for 
analysis. 
Bioluminescent Detection of CD33 Expressing Cells.  The ability for the 
C5Y82F aequorin-antibody conjugate to bind to CD33 expressed on the surface 
of HL-60 AML cells was also investigated.  Goat anti-rabbit IgG pre-coated plates 
were again used for the study.  The wells were washed three times with 150 µL 
86 
 
of buffer A.  A volume of 100 µL of 1 µg/mL rabbit anti-human CD33 polyclonal 
antibody was added to each well and allowed to incubate with shaking for 2 h at 
4 oC.  The antibody solution was removed and the wells were then washed with 
150 µL of buffer A.  HL-60 cells were collected and centrifuged at 2000 g for 10 
min to pellet the cells.  The growth media was removed and the cells were 
resuspended in buffer A and then further diluted with buffer A to the desired 
concentration.   A volume of 100 µL of HL-60 cell suspension was then added to 
wells and allowed to incubate with shaking at 4 oC for 16 h.  The wells were 
emptied and washed three times with buffer A.  A volume of 100 µL of the mouse 
anti-human CD33 monoclonal antibody conjugated to C5Y82F aequorin solution 
was added to the wells and allowed to incubate with shaking at 4 oC for 1 h.  The 
aequorin conjugated antibody solution was removed and washed three times 
with buffer A to remove any unbound protein.  Buffer B (100 µL) was added to 
each well and the bioluminescence intensity was measured for 4 s on the 
Polarstar Optima.  All measurements were taken in triplicate with the mean of the 
set plotted for analysis. 
Bioluminescent Imaging of CD33 Expressing Cells.  C5Y82F aequorin was 
incubated for 16 h with a three molar excess of coelenterazine i.  A volume of 50 
µL of the C5Y82F aequorin protein was added to 1.450 mL of buffer A in a 35 
mM dish.  A background baseline was established and then 500 µL of buffer B 
was added to the dish and the time of injection noted.  The bioluminescence was 
then captured on an Andor iXon EMCCD camera (Andor Technology, Belfast, 
Ireland) attached to a Nikon E600FN microscope for a total of 400 s.  EM gain 
87 
 
was set to 4095 and a 5 s exposure time.  Data acquisition and analysis were 
performed using Imaging Workbench 5.0 (Indec BioSystems, Santa Clara, CA, 
USA).  For the bioluminescent measurements with the HL-60 cells the cells were 
incubated for two days at 37 oC, 5% CO2 in a 35 mmpoly-L-lysine coated MatTek 
Glass Bottom Culture Dishes (MatTek Corporation, Ashland, MA) to allow the 
cells to adhere to the surface.  The cell media was then removed from the dish 
and washed 3x with 10 mM HEPES pH 7.4 containing 145 mM NaCl, 2.5 mM 
KCl, 10 mM glucose, 1 mM MgCl2, and 5 mM EDTA (buffer C) to remove any 
unbound cells.  A volume of 1.5 mL of C5Y82F aequorin labeled monoclonal anti-
CD33 antibody with coelenterazine i in buffer C was then added to the dish and 
allowed to incubate on ice for 1 h.  The solution was then removed from the dish 
and the dish was washed 2x with buffer C.  Next, 1.5 mL of buffer C was added 
back into the dish and placed under the microscope.  A stable baseline was 
obtained and 500 µL of buffer B was added to the dish and the addition time 
noted.  The bioluminescence was then captured on an Andor iXon EMCCD 
camera (Andor Technology, Belfast, Ireland) attached to a Nikon E600FN 
microscope for a total of 400 s.  EM gain was set to 4095 and a 5 s exposure 
time.  Data acquisition and analysis were performed using Imaging Workbench 
5.0 (Indec BioSystems, Santa Clara, CA, USA).   
RESULTS AND DISCUSSION 
Bioluminescence continues to emerge as a popular alternative for many of 
the diagnostic and bioanalytical methods.  The advantages of bioluminescent 
proteins are low detection limits, simple instrumentation, biocompatibility, and 
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non-toxicityto living organisms.  Aequorin, however, has been limited in  
applications due to its flash-type emission kinetics and extremely slow turnover 
rate of the bound coeleteramide after the bioluminescence occurs.  To overcome 
these shortcomings, we have employed genetic manipulation in combination with 
synthetic coelenterazines to improve aequorin’s labeling and imaging 
capabilities.  In this study, we have demonstrated that a new and improved 
aequorin mutant can be employed as a sensitive label for bioluminescent 
detection and imaging applications.  As a model system, the cell surface protein 
CD33, expressed exclusively on the surface of myeloid lineage cells, was chosen 
to demonstrate bioanalysis using aequorin as a label.   
 Our laboratory has performed extensive work with aequorin, which has 
resulted in the creation of several aequorin mutants and semi-synthetic 
aequorins exhibiting a range of both spectral and kinetic properties (56-57, 98-
100, 135). One such aequorin mutant, Y82F, was chosen for this study.  The 
Y82F mutant possesses a mutation at position 82 where a tyrosine has been 
changed to a phenylalanine.  In the wild type aequorin, the hydroxyl group on the 
tyrosine residue is engaged with the bound coelenterazine through hydrogen 
bonding (127).  Although, Tyr and Pheare very similar in size and orientation, this 
amino acid mutation alters the electronic environment experienced by the bound 
coelenterazine. In addition to this mutation, a unique cysteine was incorporated 
at amino acid position 5 of the protein through the use of specifically designed 
primers and the PCR, yielding the C5Y82F aequorin protein.  This unique 
cysteine enablessite-specific conjugation of any target molecule to aequorin 
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using well established cross-linking procedures (159).  This permits the protein to 
be used in a number of applications by only varying the target molecule without 
the need for extensive genetic modification.  Furthermore, site-specific 
conjugation provides for a reproducible production of conjugates and in 
maintaining the bioluminescent activity of the protein.  Commercially available 
aequorin labeled antibodies for thyrotropin (160) and digoxigenin (161) that 
employ the native protein have been made available; however, by introducing 
this unique cysteine, C5Y82F aequorin can be used to label essentially any 
antibody or other molecule of interest.  Furthermore, the use of the semi-
synthetic aequorin with a longer half-life expands the application of aequorin 
conjugates in imaging studies.   
 As a model system we chose the CD33 protein that is expressed on the 
surface of AML cells as the target biomolecule (155-156).  The heterobifunctional 
sulfo-LC-SPDP crosslinker was selected to link the antibody to C5Y82F 
aequorin.  First, the crosslinker was reacted with the antibody to allow the NHS 
ester portion of sulfo-LC-SPDP to react with primary amines of the lysine 
residues of the antibody.   A 10 times mole excess of the C5Y82F aequorin was 
then mixed with the modified antibody so that the 2-pyridyldithio group on the 
other end of the crosslinker would react with the sulfhydryl group of the unique 
cysteine present on C5Y82F aequorin.  The multiple SPDP conjugated sites on 
the antibody, in combination with the molar excess of aequorin available were 
utilized in an effort to permit each antibody molecule to be labeled by multiple 
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aequorin molecules, thus enhancing the detectability of the anibody-aequorin 
conjugate.    
As reported previously by our laboratory, a combination of synthetic 
coelenterazines with genetic mutations to the native aequorin has yielded 
proteins with novel and improved bioluminescent properties (98).  To confirm that 
these favorable characteristics were not compromised by the addition of a 
cysteine to the protein or the subsequent conjugation of the protein to an 
antibody of interest, the spectral properties and decay kinetics of both the free 
C5Y82F aequorin mutant and the antibody conjugated complex were examined 
with respect to the emission profile and decay kinetics.  As demonstrated in table 
3, both the free and conjugated proteins did show the expected spectral and 
kinetic characteristics.  Of particular interest to our purposes is the combination 
of the proteins with the coelenterazine i.  This combination resulted in an 
emission maximum of 506 nm, but more importantly a half-life of 16.37 s and 
18.57 s for the free and conjugated forms, respectively.  This significantly longer 
half-life compared to that of the typical aequorin bioluminescence, which is ~1 s, 
leads to more of a glow type of emission and can greatly improve the imaging 
capabilities of the protein.  The increased luminescent time will allow for larger 
exposure times, increasing the amount of light able to be captured by the 
detection equipment and allowing fewer molecules to result in a distinguishable 
signal.  The increased half-life of the proteins when paired with the 
coelenterazine i can be attributed to the internal heavy atom effect of the iodine 
which is uniquely present in this coelenterazine.  As explained by Nijegorodov  
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C5Y82F 
aequorin 
  CD33 Antibody-
C5Y82F 
aequorin 
  
coelenterazine λ max (nm) Half-life 
(s) 
coelenterazine λ max (nm) Half- 
life (s) 
ntv 501 0.95 Ntv 496 1.25 
i 506 16.37 i 506 18.57 
f 506 0.62 f 507 0.72 
cp 478 0.18 cp 484 0.26 
 
Table 3.  The emission maxima and half-lifes of both free C5Y82F aequorin and 
the C5Y82F aequorin conjugated to the anti-CD33 monoclonal antibody.  All 
measurements were performed in triplicate with the averages reported. 
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and Mabbs (162), the iodine on coelenterazine i can increase the probability of a 
transition from an excitedsinglet state to an excited triplet state.  The forbidden 
triplet to singlet transition results in an increased residence time in the excited 
states and the longer observed bioluminescence emission.  In addition to the 
longer half-life, both the free and conjugated proteins also continued to display 
the red shifted bioluminescence as compared to the native 469 nm emission.  
The coelenterazine i gave an emission maximum of 506 nm and the 
coelenterazine f an emission maximum of 507 nm.  Emission maxima around 
450 nm have been achieved with other aequorin mutant/coelenterazine analog 
pairs (98) and thus multiplexing through wavelength resolution would also be a 
future possibility with the aequorin mutants as labels. 
It has recently been discovered that free CD33 circulating through the 
blood could serve as a marker for important clinical applications when dealing 
with AML patients.  Free CD33 has been shown to be capable of discriminating 
between various pathophysiological states, to correspond with survival 
prognosis, and possibly be an indicator of tumor cell turnover (158, 163-164).  In 
addition, with the antibody based AML treatment strategies, free CD33 would act 
as a major inhibitor of the antibody-drug complex reaching the desired target and 
play a role in the efficacy and dosing requirements of the drug.  Being able to 
quickly and efficiently determine free CD33 concentrations in physiological fluids 
has the potential to be a key requirement for future dosing decisions along with a 
simple non-invasive method to track and monitor disease progression.  
Consequently, the C5Y82F aequorin labeled anti-CD33 antibody was used to 
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develop a microtiter plate based immunoassay.  The high sensitivity of 
bioluminescence allowed free CD33 to be detected down to 1.87x10-18 moles, as 
shown in figure 21.  The microtiter plate platform would also allow numerous 
samples to be investigated in a very short time.  
Cell surface expressed CD33 has also shown to be a useful entity, being 
used as a therapeutic target by drugs such as Mylotarg (157). Thus we also 
evaluated the use of C5Y82F aequorin labeled antibody to detect CD33 
expressed on the surface of AML cells (HL-60 cells, ATCC, Manassas, MA).  A 
quantifiable bioluminescent signal, significantly above the background, was 
obtained from as few as three AML cells (figure 22).   
As previously mentioned, current explorations with bioluminescence 
imaging are typically limited to luciferase based systems, as the continuous 
administering of D-luciferin and availability of ATP allows the bioluminescence to 
be produced and observed continuously.  The slow turnover rate and flash-type 
kinetics of aequorin have not been favorable on the imaging forefront and have 
typically limited aequorin to the visualization of Ca2+ dynamics, availability, and 
signaling (165-167). In a step in the direction towards the use of aequorin outside 
of the typical Ca2+ imaging, we show that a quantifiable signal from the C5Y82F 
aequorin mutant was observed several minutes after the initiation of the 
bioluminescent reaction on a typical imaging microscope (figure 23a, 23b).  This 
longer emission profile will allow the increased integration and camera exposure 
times necessary for the detection of the bioluminescent signal. The C5Y82F 
aequorin labeled antibody was also successful in indicating the presence of AML  
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Figure 21.  Dose response plot for free CD33.  All points are the average of 
triplicate measurements ± one standard deviation.  Measurements were taken in 
a volume of 100 µL.  Error bars not visible are concealed by the points. 
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Figure 22.  Bioluminescence intensity observed from differing amounts of HL-60 
cells expressing the CD33 surface antigen. All points are the average of triplicate 
measurements ± one standard deviation.  Error bars not visible are concealed by 
the points. 
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Figure 23. A. The bioluminescence response observed after the addition of Ca2+ 
to a solution containing free C5Y82F aequorin with respect to time.  B.  The 
image taken of the solution before (left) and after (right) the addition of Ca2+ to 
the free protein in solution.  C.  The top imager is the bright field image of the 
field of view of AML cells bound to the surface of dish with the aequorin 
conjugated antibody bound to the surface.  The bottom two images are the field 
of view before (left) and after (right) the addition of Ca2+ showing the antibody 
was bound to the surface of the cells.  
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cells expressing the CD33 antigen on the cell surface (figure 23c).  In addition, 
the unique cysteine and the ability to visualize the purified protein will allow the 
labeling with this protein to be tailored to specific needs that do not necessitate 
the genetic creation of an entirely new protein complex. 
 
CONCLUSIONS 
Bioluminescence offers a number of advantages when considering the 
requirement for extremely sensitive detection.  The biocompatibility of 
bioluminescent proteins, the elimination of sample auto-fluorescence, and 
removal of the need for an excitation source all make bioluminescent an 
excellent choice as an inexpensive and efficient labeling option.  Herein we 
describe an aequorin mutant, C5Y82F aequorin, which further expands the 
possibilities of using aequorin bioluminescence in a clinical and research setting.  
A unique cysteine was added to the protein to allow for quick and effective 
conjugations of any molecule of interest to aequorin.  As a model system, an 
immunoassay for the AML surface antigen, CD33, was developed with a C5Y82F 
aequorin labeled monoclonal CD33 antibody.  Free CD33 has recently been 
shown to be of clinical significance (158) and we were able to achieve excellent 
detection of the protein, down to 1.87x10-18 moles.  We were also able to 
demonstrate the ability to detect as few as three individual AML cells using the 
aequorin-antibody conjugate.  Furthermore, we were able to show that the 
potential for imaging with the engineered protein exists, demonstrating an 
observable bioluminescent signal for several minutes with a typical imaging 
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microscope.  As imaging instrumentation continues to advance and improve, a 
versatile bioluminescent label could push the imaging capabilities forward for 
highly sensitive analysis. 
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CHAPTER FIVE 
 
CYCLIC AMP RECEPTOR PROTEIN- AEQUORIN MOLECULAR SWITCH 
FOR CYCLIC AMP 
Adapted with permission from: Scott, D., Hamorsky, K., Ensor, C. Anderson, K., 
Daunert, S., 2011.  Cyclic AMP Receptor Protein-Aequorin Molecular Switch for 
Cyclic AMP. Bioconjugate Chem, 22(3), 475-481. Copyright 2011 American 
Chemical Society. 
INTRODUCTION 
Nature is able to produce proteins exhibiting highly desirable 
characteristics in terms of function, specificity, and efficiency, unmatched by 
synthetically developed molecules.  Driven by this phenomenon, many scientists 
utilize and manipulate natural proteins to achieve the specificity and response 
that many of today’s assays and detection methods strive for.  But there is not 
always a single natural protein suitable for a task at hand.  In some instances it 
would be advantageous to couple the functions of two completely unrelated 
proteins to work together as one to achieve a desired function-e.g., to quantify an 
analyte binding induced conformational change of a protein that naturally would 
be undetectable.Molecular switches can be the solution to accomplish such 
tasks.  A protein molecular switch is defined as an entity that couples signal to 
functionality (168).  For example, a protein molecular switch responds to an input 
signal by producing an “on/off” output signal.  Such a protein could be 
constructed by genetically combining the coding sequence of one protein with 
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that of another, creating a hybrid fusion protein with a completely new function, 
which displays the discrete functions of the individual proteins (168-171).  To that 
end, we have inserted the flexible hinge motion binding protein, cyclic AMP 
(cAMP) receptor protein (CRP), into the genetic sequence of the bioluminescent 
protein aequorin to create a functional fusion hybrid protein, CRPAEQ.  The 
separate proteins were genetically attached in a manner so that the 
conformational change experienced by CRP upon binding to cAMP results in a 
loss of bioluminescent signal of the aequorin portion of the hybrid protein (figure 
24).     
Aequorin (figure 25) is a calcium dependent bioluminescent protein found 
naturally in the jellyfish Aequorea victoria.  Aequorin was originally isolated in 
1962 by Shimomura et al (172-173).  The complete aequorin complex is 
composed of the apoprotein, apoaequorin, and the organic chromophore 
coelenterazine.  Apo-aequorin contains 189 amino acids arranged to form four 
EF-hand sequences (127, 174) that fold to create the hydrophobic core for the 
stabilization of the coelenterazine allowing for the bioluminescence to occur.  In 
the presence of molecular oxygen and Ca2+, aequorin undergoes a 
conformational change that allows for the oxidation of coelenterazine to 
coelenteramide with the release of CO2 and the emission of light at 469 nm 
(175).   Employing aequorin as a signal generating molecule has advantages 
over employing chemical or protein-based fluorescent probes because since the 
emission of light is the result of an internal biochemical reaction there is no need 
for an excitation source causing negligible background signal and leading to  
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Figure 24.  Schematic of the response of the CRPAEQ molecular switch to the 
presence of cAMP.  Initially the coelenterazine free CRPAEQ complex is not 
bioluminescent.  Upon stabilization of the chromophoric coelenterazine and the 
addition of Ca2+ the complex will emit the bioluminescent flash, characteristic of 
normal aequorin.  Following the cAMP induced conformational change the two 
halves of aequorin are positioned too far apart to form the active aequorin 
complex and thus decreases the observed bioluminescent intensity. 
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Figure 25.  The crystal structure of aequorin with coelenterazine bound in the 
hydrophobic pocket. Amino acids 1-47 are shown in blue and amino acids 48-
189 in red representing the fragments in which aequorin was split. 
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exceptional detection limits. In addition aequorin is environmentally friendly and 
thus it does not require special attention for disposal (176-178). 
CRP regulates transcription of over 150 genes in Escherichia coli (179). It 
is allosterically activated by the binding of cAMP, which causes CRP to undergo 
a conformational change that allows for the binding of specific DNA Sequences 
(180-182).  In nature CRP exists as a homodimer of two identical subunits each 
containing 209 amino acids (23.6 kDa molecular mass) (182).  Each subunit folds 
into two domains: the N-terminal domain (residues 1-133) responsible for the 
dimerization of CRP and housing the higher affinity cAMP binding pocket, and 
the C-terminal domain (residues 139-209), which is responsible for the 
interaction with DNA through a helix-turn-helix motif (179, 182-183).  Amino acids 
134-138 form a flexible hinge that couples the two domains through covalent 
interactions (182).  Each subunit contains two cAMP binding sites.  The N-
terminal domain houses the higher affinity cAMP binding site, which binds cAMP 
in the μM range.  The second cAMP binding site is located between the hinge 
and the turn of the helix-turn-helix motif and only binds cAMP when it is present 
at mM concentrations.  Thus, the CRP protein is believed to exist in three states: 
free CRP with no cAMP bound, CRP-(cAMP)2 when each subunit contains one 
bound cAMP molecule in the higher affinity binding site, and CRP-(cAMP)4 when 
each subunit has two cAMP molecules bound, one each in the higher and lower 
affinity binding sites (179, 184-185).  The binding of cAMP by the higher affinity 
binding site is what induces the first conformational change in the N-terminal 
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domain, which is then conveyed to the C-terminal domain resulting in a further 
conformational adjustment allowing the binding of DNA (179). 
The large diversity of biological molecules exhibiting high specificity and 
affinity for analytes of interest has lead to the increasing use of these molecules 
for the development of novel biosensing systems.  Molecular switches have been 
created to translate the binding induced conformational change of many of the 
protein biomolecular recognition elements into a quantifiable signal in the forms 
of altered fluorescence emissions, electron transfer, and biochemical activity 
among others.  Examples of analytes targeted by such switches include a 
number of different sugars, secondary messengers, drug molecules, and proteins 
to name a few (186).  Molecular switches have also been developed based on 
DNA-base mispairing to monitor changes in the pH of the local environment 
(187).  However very rarely has bioluminescence, with the advantages 
mentioned previously, been employed for the evolution of a molecular switch.   
Examples can be seen with the molecular switches created for glucose using the 
bioluminescent proteins AEQ (170) and firefly luciferase (188), but are limited 
beyond these examples. 
Herein, we have employed CRP and aequorin in the construction of a 
molecular switch hybrid protein, CRPAEQ capable of the detection of cAMP.  In 
cells, cAMP is an omnipresent secondary messenger with a plethora of functions 
including the regulation of cellular events (189-193).  The ability to monitor 
cellular cAMP should provide insight into many cellular processes and responses 
from external stimuli. CRP is a favorable candidate for use in a molecular switch 
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given that its hinge region allows for the protein to move in a clamping-type of 
motion when binding to cAMP, allowing for the possibility of a molecule attached 
to the ends of the protein to experience a greater change in position when the 
motion caused by the conformational change occurs.  In our “on/off” molecular 
switch, cAMP provides the input signal when it selectively binds to CRP and 
induces the conformational change in the native protein, while aequorin provides 
the output signal in the form of the bioluminescence emission.  To prepare the 
hybrid protein, aequorin was split in two fragments and attached to the N and C 
terminal ends of CRP to take advantage of this characteristic.  We had previously 
observed that that there is a flexible loop between the EF hands I and II of 
aequorin, corresponding to amino acids 46-51, that allow for insertion of another 
protein without significantly disrupting the rest of the tertiary structure of the 
protein (170).  We, therefore, hypothesized that by inserting CRP between amino 
acids 47 and 48 in addition to adding a linker sequence to both ends of the CRP 
molecule the aequorin fragments would have enough flexibility and freedom to 
reunite and reassemble to form the active bioluminescent aequorin complex.   
EXPERIMENTAL PROCEDURES 
Materials.  Tris free base–Tris(hydroxymethyl)amino methane was purchased 
from Serva (Heidelburg, Germany).  Disodium ethylenediaminetetraacetate 
(EDTA), Luria-Bertani (LB) Agar, and LB Broth were purchased from Fischer 
Scientific (Fair Lawn, NJ). Urea, glucose, albumin from bovine serum (BSA), 
calcium chloride, 3’-5’-cyclic adenosine monophosphate, 3’-5’-cyclic guanosine 
monophosphate, 3’-5’-cyclic inosine monophosphate, 3’-5’-cyclic uridine 
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monophosphate, 3’-5’-cyclic cytosine monophosphate, ampicillin sodium salt, 
chloramphenicol, kanamycin monosulfate, and ethidium bromide were purchased 
from Sigma-Aldrich (St. Louis, MO). Sodium Dodecyl Sulfate (SDS) was 
purchased from Curtin Mathesin Scientific, Inc. (Houston, TX).  Isopropyl--D-
thiogalactoside (IPTG) was purchased from Gold Biotechnology, Inc. (St. Louis, 
MO). DEAE Fast Flow was purchased from GE Life Sciences. Poros 50 HQ was 
purchased from AB Applied Biosystems (Foster City, CA). The Bradford protein 
assay kit was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA). Mini-
prep kits and gel extraction kits were purchased from Qiagen (Valencia, CA). 
Top10 and Top10F’ chemical competent cells were purchase from Invitrogen 
(Carlsbad, CA). The plasmid, pET28(a)+, BL21(DE3)pLysS chemical competent 
cells, and BL21(DE3) cells were purchased from Novagen (Madison, WI). 
JM109(DE3) chemical competent cells were purchased from Promega (Madison, 
WI).  Gel code blue stain was purchased from Pierce (Rockford, IL). T4 DNA 
ligase, alkaline phosphatase, and EcoRI, HindIII, and NheI, restriction enzymes 
were purchased from Promega (Madison, WI). Pfu Ultra polymerase and Taq 
polymerase were purchase from Strategene (Ceder Creek, TX).  All chemicals 
were reagent grade or better and all aqueous solutions were prepared using 16 
mΩ deionized distilled water produced by a Milli-Q water purification system 
(Millipore, Bedford, MA). 
Apparatus. Polymerase chain reactions (PCR) were performed using an 
Eppendorf Mastercycler Personal (AG, Hamburg). DNA electrophoresis was 
performed using a FB105 Fischer Biotech Electrophorese Power Supply 
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(Pittsburgh, PA) and the gels were visualized using a UV Transilluminator (UVP, 
Upland, CA). OD600 readings were taken using a Spectronic 21D (Milton Roy, Ivy 
Land, PA). Cells were sonicated using a Fischer Scientific 550 Sonic 
Dismembrator (Pittsburg, PA). Proteins were expressed by incubating bacteria at 
37oC on a Forma Scientific Orbital Shaker (Waltham, MA) and harvested using a 
Beckman J2MI centrifuge (Palo Alto, CA). Fusion proteins were purified using a 
BioCad Sprint Perfusion Chromatography System (Perseptive Biosystems, 
Framingtion, MA). Purity of the fusion proteins were verified by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using Invitrogen 10-20% 
Tris-glycine gels in an Invitrogen X Cell Sure Lock Mini Cell (Carlsbad, CA). 
Bioluminescence measurements were made on an Optocomp I test tube 
luminometer (MGM Instruments, Inc., Hamden, CT) using Fischer borosilicate 
12x75mm disposable glass tubes (Pittsburg, PA).  Emission spectra were taken 
on a custom made SpectroScan instrument from Sciencewares (Farmingham, 
MA). Circular dichroism measurements were performed on a Jasco J-810 circular 
dichroism system (Easton, MD). 
Construction, Expression, and Purification of CRPAEQ fusion protein.  The 
CRPAEQ gene was produced by an overlap PCR method as shown in figure 26.  
More specifically the PCR was used to amplify the coding sequence for amino 
acids 1-47 of aequorin and to introduce an EcoRI restriction site on the 5’ end of 
the coding sequence along with a sequence coding for a linker region with the 
sequence SGGGGS followed by the restriction sites for PstI and SacI at the 3’ 
end.  The coding sequence for amino acids 48-189 of aequorin was amplified  
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Figure 26. Schematic of the stepwise design of the plasmid containing the gene 
for the CRPAEQ fusion protein.  Briefly; the individual fragments of AEQ (amino 
acids 1-47 and 48-189) and CRP are PCR amplified while introducing unique 
restriction sites.  Overlap PCR is then used to attach to two AEQ fragments 
followed by the ligation into the expression vector achieved through the cutting of 
unique restriction sites and ligated back together.  The CRP gene is then inserted 
into the middle of the AEQ gene through the same restriction and ligation 
method.  A schematic of how the fusion protein could potentially appear if 
crystalized is shown on the right. 
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separately introducing PstI and SacI restriction sites and the linker region at the 
5’end and a HindIII restriction site 3’ end of the coding sequence. By utilizing the 
aequorin 1-47 forward primer and the aequorin 48-189 reverse primer in an 
overlap PCR reaction the complete aequorin gene was reassembled with the 
linker region followed by the PstI and SacI restriction sites followed by another 
linker region inserted between amino acids 47 and 48 of aequorin.  The overlap 
aequorin product was ligated into the EcoRI and HindIII sites of pIN4 to yield 
pOLAEQ.  The gene for CRP was then amplified with PstI and SacI restriction 
sites introduced on 5´ and 3´ ends of the gene, respectfully, and inserted into the 
PstI and SacI sites of the aequorin gene in pIN4 to yield pCRPAEQ.  The 
resultant fusion protein gene encodes for the split aequorin protein attached to 
the ends of CRP as follows: AEQ1-47-linker-CRP-linker-AEQ 48-189.  After 
unsuccessful expression attempts were performed it was decided to remove the 
CRPAEQ fusion protein gene from the pIN4 plasmid and insert it into the 
pET28(a)+ plasmid.  The PCR was used to introduce a NheI restriction site at the 
5´ end of the coding sequence while conserving the HindIII restriction site on the 
3´ end.  The CRPAEQ gene was then ligated into pET28(a)+ to produce 
pCRPAEQ2.  The DNA was then transformed into competent BL21(DE3) cells. 
Sequencing to confirm the correct DNA orientation was performed by the 
University of Kentucky Advanced Genetics Technology Center (AGTC).   
Overnight cultures of the bacteria cells were grown at 37oC at 250 rpm in 5 
mL LB broth containing 30 μg/mL Kanamycin.  This culture was used to inoculate 
500 mL of LB broth containing 30 μg/mL Kanamycin and grown at 37oC at 250 
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rpm.  Once the OD600 reached 0.4 the cells were induced with IPTG to a 
concentration of 1 mM and the bacteria were allowed to grow overnight.  The 
cells were collected by centrifugation at 12,000 rpm, 4oC for 15 minutes.   
The CRPAEQ protein was only found to be expressed in inclusion bodies 
under a number of different conditions and thus required to be purified from the 
inclusion bodies.  The cell pellet was dissolved in 20 mL of 30 mM Tris/HCl pH 
7.5 2 mM EDTA buffer and lysed by two, 5 minute cycles of sonication alternating 
10 s on/ 10 s off.  The lysis mixture was then centrifuged for 10 min at 12,000 
rpm and 4oC to collect the inclusion bodies.  The pellet was then washed 
consecutively with 30 mM Tris/HCl pH 7.5, 2 mM EDTA, 150 mM NaCl; 30 mM 
Tris/HCl, pH 7.5, 2 mM EDTA, 1% Triton X-100; and then 30 mM Tris/HCl, pH 
7.5, 2 mM EDTA, 5 mM CaCl2 with the protein collected in between the washes 
by centrifugation at 12,000 rpm and 4oC for 10 minutes. The pellet was then re-
suspended in 3 mL/g of pellet of 30 mM Tris/HCl, pH 7.5, 2 mM EDTA, 6 M Urea 
and allowed to rotate overnight at 4 oC.  The mixture was then centrifuged at 
12,000 rpm and 4 oC for 20 minutes and the supernatant, which contained the 
denatured CRPAEQ protein, was reserved.  The denatured protein was purified 
using a DEAE Sepharose Fast Flow ion exchange column on a BioCAD Sprint 
Perfusion Chromatography System.  The column was equilibrated with 4 column 
volumes of equilibration buffer (30 mM Tris/HCl, pH 7.5, 2 mM EDTA, 6 M urea).  
The denatured protein supernatant was loaded onto the column and the column 
was washed with 3 column volumes of equilibration buffer.  The protein was then 
eluted with elution buffer (30 mM Tris/HCl, pH 7.5, 2 mM EDTA, 6 M urea, 1 M 
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NaCl)  using a 0 to 50% elution buffer gradient over 10 column volumes.  Five 
mL fractions were collected and a SDS-PAGE was used to confirm the fractions 
containing the CRPAEQ protein, which were then pooled together.  The urea was 
removed through dialysis in 30 mM Tris/HCl, pH 7.5, 2 mM EDTA to allow the 
protein to refold.  Protein refolding in the correct orientation was verified by 
bioluminescent activity of the aequorin portion of the protein.  The protein 
concentration was determined to be 1.784 mg/mL using a Bradford protein 
assay.   
Bioluminescent Half-life Determination.  A final concentration of 1 µg/mL of 
coelenterazine was added to the apoCRPAEQ fusion protein and left for 18 h at 
4 oC.  Ten μL of the coelenterazine charged CRPAEQ mixture was added to a 
glass culture tube and the bioluminescence was measured using the Optocomp I 
test tube luminometer and the signal was collected for 10 s.  The half life was 
determined using the one phase exponential decay kinetics equation from 
GraphPad Prism.  The same procedure was followed for the half life 
determination of the CRPAEQ fusion protein in the presence of 0.1 mM cAMP.   
Emission spectra.  The CRPAEQ protein was charged with several native 
coelenterazine for 18 h at 4 oC.  The emission spectra of the protein with the 
native coelenterazine was then measured on the SpectroScan instrument from 
ScienceWares (Framingham, MA, USA). 
cAMP Detection by CRPAEQ Fusion Protein.  The CRPAEQ fusion protein 
was diluted to 1x10-5M in 30 mM Tris/HCl, pH 7.5, 2 mM EDTA and 
coelenterazine was added to a final concentration of 1 μg/ml.  Ninety μl of the 
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CRPAEQ/coelenterazine mixture was placed in a 1.5 ml polypropylene 
microcentrifuge tube and 10 μl of the corresponding cAMP standard was added 
to achieve the desired concentration and allowed to charge at 4oC for 18 h.  Ten 
μl of the charged mixture was added to a disposable glass tube and the 
bioluminescence was measured using the Optocomp I luminometer as described 
above. The bioluminescent signal was integrated over six s.   
Selectivity Study.  To determine the selectivity of the CRPAEQ fusion protein 
the stock apoCRPAEQ fusion protein was diluted to 1x10-5 M and coelenterazine 
added to a final concentration of 1 μg/ml.  Ninety μl of this mixture was added to 
1.5 ml polypropylene microcentrifuge tubes along with 10 μl of a cyclic nucleotide 
corresponding to a final concentration of 0.1 mM.  The cyclic nucleotides tested 
consisted of cyclic guanosine monophosphate (cGMP), cyclic cytidine 
monophosphate (cCMP), cyclic uridine monophosphate (cUMP), cyclic inosine 
monophosphate (cIMP) and were prepared in 30 mM Tris/HCl, pH 7.5, 2 mM 
EDTA.  The tubes were allowed to charge 18 h at 4oC then 10 μl of each tube 
was added to a disposable glass tube.  Bioluminescence was measured using 
the Optocomp I luminometer as described above.  
Cellular cAMP Monitoring.  Three separate BL21(DE3) E. coli cell cultures 
were grown at 37 oC in 8 mL LB broth at 250 rpm to an O.D.600 ~ 0.5.  One 
culture was grown in the presence of 100 µM glucose, another in the presence of 
50 mM inorganic phosphate, and the third without any additions.  Once the 
O.D.600 of 0.5 was reached the cell cultures were distributed into 1 mL aliquots.  
Two µL of toluene was added to each aliquot and shaken at room temperature 
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for 10 minutes at ~200 rpm.  Fifty µL of the cell solution was then added to 100 
µL of a solution of CRPAEQ in 30 mM Tris/HCl, pH 7.5, 2 mM EDTA with 1 µL 
coelenterazine and allowed to charge 18 h at 4 oC.  Ten µL of each solution was 
then added to a disposable glass tube and the bioluminescent activity was 
observed using the Optocomp I as described above and integrating the signal 
over 6 s.   
RESULTS AND DISCUSSION 
Bioluminescence has a number of advantages over fluorescence as a 
bioanalytical tool including extremely low background, highly sensitive detection 
and the ability to be used in the absence of an external excitation light source.  
Exhibiting these quality characteristics aequorin and has been shown to be a 
very sensitive label for a variety of applications (176-178).  CRP is natively found 
in Escherichia coli and is used to regulate transcription of over 150 genes in the 
organism.  CRP is allosterically activated by cAMP binding and upon binding 
cAMP undergoes a conformational change (181-182, 194). This conformation 
change combined with the bioluminescent activity of aequorin can be integrated 
in the form of a fusion protein to create a very efficient and biologically relevant 
molecular switch to be implemented in a cAMP sensing system.   
Much care, however, must be exhibited when genetically engineering the 
two proteins to be expressed together as a fusion protein.  Aequorin consists of 
four EF hands, three of which bind calcium (EF-hand I, III, and IV).  It also has 
three triads consisting of the amino acids tryptophan, tyrosine, and histidine that 
are involved in the detainment of the chromophoric coelenterazine in the active 
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site of the protein (170).  These components are very important to the function of 
aequorin and must be conserved to preserve bioluminescent activity.  Disrupting 
any of the structural components by inserting CRP would render the resulting 
protein bioluminescently inactive and thus useless for the designed function.  
However, there is a flexible loop on the exterior of the protein between EF-hand I 
and EF-hand II corresponding to amino acids 46-51 that has the ability to house 
a large sequence without disturbing the functional components of aequorin 
mentioned previously (170). Thus CRP was inserted between amino acids 47 
and 48 of aequorin.  A linker region was also included in between the aequorin 
and CRP fragments to allow for extra flexibility and aid in the correct folding of 
the individual portions of the protein.  The gene encodes for the split aequorin 
protein sequence attached to the ends of the CRP sequence as follows: AEQ1-
47-linker-CRP-linker-AEQ 48-189 (figure 26).  The fusion protein coding gene 
was then ligated into the pET28(a)+ expression plasmid.   Following the 
transformation of the plasmid into BL21(DE3) cells an acceptable level of 
expression was achieved, however the protein was expressed in inclusion 
bodies.  Several changes to the expression of the protein were attempted in 
order to avoid the formation of inclusion bodies including growth at a lower 
temperature and inducing with decreased amounts of IPTG with no avail 
resulting in the need to purify the protein as inclusion bodies followed by refolding 
of the protein. The inclusion bodies were solubilized through the use of urea and 
purified on a DEAE Sepharose ion exchange column also in the presence of 
urea.  Refolding of the fusion protein was achieved by removing the urea through 
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dialysis with 30 mM Tris/HCl, pH 7.5, 2 mM EDTA buffer.  The purity of the 
protein was confirmed by a single prominent band at ~46 kDa on a SDS-PAGE 
gel, corresponding to the size of the CRP monomer added to that of aequorin.  
The protein also exhibited bioluminescent activity when charge with the 
coelenterazine and exposed to a Ca+ containing solution.  The purified CRPAEQ 
was found to have a final concentration of 1.784 mg/ml as determined by a 
Bradford Assay.   
The molecular switch showed a reproducible, decrease in signal 
corresponding to an increase in cAMP concentration from about 1x10-7 M to 
1x10-3 M (figure 27).  It has been reported that CRP contains two cAMP binding 
sites, one higher affinity site located in the N-terminal domain and also a lower 
affinity site contained between the hinge region and turn of the helix-turn-helix 
motif of the protein (182, 185). The higher affinity cAMP binding site binds cAMP 
in the μM range, and the lower affinity site is bound when cAMP is in the mM 
range (179) keeping the observed response consistent with previous studies and 
permitting the sensor to be suitable for measuring cAMP levels of biologically 
relevant samples (195).  As reported above, as the cAMP concentration 
increases, the bioluminescent signal from the aequorin portion of the fusion 
protein decreases.  It has been shown previously that CRP undergoes a hinge 
type conformational change upon the binding of cAMP (182).  This leads to the 
presumption that upon binding of cAMP, the conformation change experienced 
by CRP occurs in a manner which causes the two halves of aequorin to move in  
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Figure 27.  Dose-response plot of the observed response of the CRPAEQ fusion 
protein to varying concentrations of cAMP.  Data points are the mean of three 
samples in triplicate ± one standard deviation.  Error bars not visible are 
concealed by the data point. 
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Figure 28.  Selectivity study results.ΔI represents the intensity change from the 
control in relative light units (RLU) after the addition of the respective cyclic 
nucleotides.  Data represent the mean of three samples in triplicate ± one 
standard deviation. 
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opposite directions from each other based on their original position.  With the 
spatial separation increased between the two halves, the bioluminescently active 
complex is unable to be reformed thus inhibiting the production of light upon the 
binding of Ca2+ by the aequorin portion of the protein as shown above in figure 
24. 
A selectivity study was performed to determine the effect other cyclic 
nucleotides would have on the activity of the fusion protein.  The data show 
CRPAEQ to be selective for cAMP (figure 28).  Cyclic UMP (cUMP), cyclic CMP  
(cCMP), and cyclic IMP (cIMP) were found to be negligible in affecting the 
bioluminescent signal.  cGMP, the most similar to cAMP in terms of structure, 
was found to affect the signal, but to a lower extent than that of cAMP.  cAMP 
decreased the bioluminescent signal from CRPAEQ by 47% while, cGMP only 
caused a 26% decrease in the signal.  
The spectral properties of the fusion protein were compared to that of the 
individual aequorin.  The half-life of the bioluminescence from the aequorin of the 
CRPAEQ fusion protein was found to be 1.5 s without cAMP and 1.9 s with 
cAMP bound, similar to the 1 s half-life of the cysteine free mutant of aequorin 
(196). The emission maximum was slightly blue shifted to 480 nm, but still similar 
to the 471 nm emission shown by the cysteine free aequorin (196).  This shows 
that although the CRP protein has been inserted in between the two halves of 
aequorin, the kinetics of the protein have not been greatly affected.   
To test the switches potential in cAMP monitoring applications Escherichia 
coli was used as a model system.  It has been shown previously in Escherichia 
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coli that inorganic orthophosphate is able to increase the amount of intracellular 
cAMP via two separate mechanisms. The inorganic orthophosphate not only 
stimulates adenylyl cyclase, the enzyme responsible for cAMP synthesis, but 
also slows down the degradation of cAMP by inhibiting cAMP 
phosphodiesterase, the enzyme responsible for the degradation, consequently 
elevating the cAMP levels in the cell (197).   Glucose has been shown to possess 
a reverse effect on adenylyl cyclase, decreasing its activity, resulting in lower 
intracellular cAMP concentrations (198).  Thus in an effort to allow for changes in 
cellular cAMP levels Escherichia coli cultures were grown in the  presence of 
either inorganic orthophosphate or glucose in hopes of increasing and 
decreasing cellular cAMP levels respectively.   Previous studies also indicate the 
use of toluene to increase cellular permeability is an effective and more efficient 
method to allow for the quantification of intracellular cAMP (197-198).  After 
allowing cultures to grow in the presence of the specified molecules, the 
CRPAEQ molecular switch was utilized to detect changes in cellular cAMP 
levels.  As shown in figure 29 the molecular switch provides a very reliable 
method to monitor increases and/or decreases in cellular levels of cAMP in 
response to different external stimuli without the need to lyse the cells.  Although 
aequorin has traditionally been employed as a Ca2+ probe, in our experiments we 
employ EDTA buffered solutions to prevent uncontrolled bioluminescence 
emission triggered by endogenous Ca2+.  This made sure the change in the 
bioluminescent signal was due solely to the changes in cAMP levels and not 
Ca2+ fluctuation.   
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Figure 29.  The bioluminescent signal observed from the CRPAEQ molecular 
switch when exposed to cell cultures grown in the presence of either glucose, 
inorganic orthophosphate, or with no additions (Control). Concentrations were 
calculated from dose response plot of known concentrations.  Points are mean of 
three samples in triplicate ± standard deviation. (** P value < 0.05 as determined 
via ANOVA compared to the Control culture). 
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There are currently a variety of cAMP detection methods that have been 
developed and explored, including radiometric and antibody based assay 
systems (199).  The radiometric systems pose the safety issues and disposal 
problems while the antibody based systems require expensive antibodies.  
Among those, we can cite the commercially available cAMP-GloTM Assay from 
Promega (Promega Coorporation, Madison, WI, www.promega.com) and the 
LANCE®Ultra cAMP detection kit from PerkinElmer (PerkinElmer, Waltham, MA, 
www.perkinelmer.com).  The cAMP-GloTM assay uses a luciferase and protein 
kinase A to indirectly monitor the cAMP levels.  cAMP binds to protein kinase A, 
releasing its catalytic subunits, which then catalyze the transfer of a terminal 
phosphate from ATP to the protein kinase A substrate, reducing the levels of 
ATP in the solution.  The remaining ATP is then quantified with luciferase.  
Therefore, as the amount of cAMP increases, more ATP is consumed by the 
protein kinase A reaction, causing a decrease in the luminescence observed.  
The LANCE®Ultra cAMP detection kit is a competitive binding assay between 
europium chelate labeled cAMP molecules and free cAMP in the sample.  The 
two cAMP forms compete for binding sites on a fluorescently labeled anti-cAMP 
antibody.  When the europium chelate molecule is excited, if it is bound to the 
antibody it transfers non-radatively energy to the attached fluorescent label, 
which, in turn, is excited and emits a distinct fluorescence signal.   However, 
when the free cAMP is bound to the labeled antibody, there is no europium 
chelate capable of transfering energy to the fluorescent label, and therefore the 
fluorescence emission observed corresponds to that of the europium on the 
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labeled cAMP molecules.  Thus, the intensity of the emission from the 
fluorescently labeled antibody is inversely proportional to the amount of free 
cAMP in the solution. Our CRPAEQ molecular switch offers a unique alternative 
to the available methods and creates a more direct detection method than those 
of the existing technologies. The ability of our switch to directly translate the 
binding of cAMP to a change in the bioluminescence intensity without 
requirement for the addition of reagents at different steps, results in a faster 
method of detection.  Moreover, our switch is also eliminates the need for 
expensive labeled cAMP molecules and antibodies.  This direct detection also 
reduces the possibility of the results being inaccurate due to potential changes in 
the concentration of the complementary assay molecules, such as ATP, that 
could be caused by unrelated cellular events or responses.  In addition, 
bioluminescence offers the advantage of eliminating background interference 
from autofluorescent molecules commonly present in cellular and physiological 
samples. The CRPAEQ molecular switch provides a reagentless detection 
method saving resources while offering a safer and more environmentally friendly 
system.  The hybrid protein which is the basis of the molecular switch, is 
expressed as a single protein.  Thus, if the apoprotein is expressed and 
reconstituted in vivo, it could potentially find applications in cellular detection.   
CONCLUSIONS 
In summary, it has been demonstrated that the functions of two unrelated 
proteins, each with desirable characteristics can be successfully coupled in the 
development of a bioluminescent molecular switch which can be used for 
123 
 
detection and monitoring of a specific analytes.  CRP, a cAMP selective binding 
protein, was fused with a split aequorin, a photoprotein that generates a 
bioluminescent signal.  When combined, the fusion hybrid protein results in a 
molecular switch capable of highly sensitive cAMP detection.  This switch offers  
a number of advantages over currently employed methods in terms of simplicity, 
safety, and environmental friendliness.  Moreover, it is envisioned that it would 
find a host of applications in a number of fields, such as biomedicine, 
biotechnology, medicinal chemistry, pharmacology, etc.  Finally, CRPAEQ joins a 
very short list of bioluminescent molecular switches.  Very rarely has a protein 
been able to be split, and re-united under desired conditions to give a reliable 
response able to be used for quantification of a specific analyte.  This could open 
the doors to a whole new class of detection molecules to be implemented in 
various monitoring applications, allowing for a better understanding of 
mechanisms and behavior of complex biological and cellular systems as well as 
for elucidating the interactions and mechanisms of not-well characterized 
naturally occurring proteins. 
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CHAPTER SIX 
 
A PORTABLE, REAGENTLESS, OPTICAL SENSOR CATHETER FOR REAL 
TIME IN VIVO POTASSIUM DETECTION  
 
INTRODUCTION 
The potassium ion, K+, plays a critical role in many physiological 
processes and can be a valuable marker for a variety of applications, including 
postoperative monitoring, signaling of ischemia, and renal failure, among others 
(200-203). However, there is no commercially available sensor that can monitor 
in vivo the variations of potassium ion concentrations in real time. Thus the need 
for a fast and reliable in vivo potassium ion sensing system, capable of real time 
monitoring would be valuable for many clinical applications, providing instant 
feedback, allowing for immediate action, and efficient monitoring, management 
and treatment of patients. Current methods of choice for potassium detection 
include flame emission spectroscopy and ion-selective electrodes (204). 
Although very accurate with regard to potassium analysis, the possibility of in 
vivo detection with these methods is difficult.  Although previously, there have 
been claims of real time K+ detection systems (205), they did  not demonstrate 
their ability for in vivo monitoring and were never commercialized (206). More 
recently, selective ionophore optodes incorporated into polymeric membranes 
have been employed for the quantification of potassium (207-208).  A variety of 
potassium sensing optodes have been implemented previously for use in 
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analytical assays (207-208), including integration into microfluidic platforms 
(209),  microspheres and microspots (210-211), to name a few.   Coupling of 
these optodes with fiber optics may provide an avenue by which a real time 
potassium sensor could be developed.  The deposition of a fluorescent optode 
membrane onto the tip of a custom made fiber optic system has lead to the 
development of a sensor suitable for integration into a catheter-based system for 
the in vivo detection of K+ ions in a variety of clinical settings. 
Herein, we prepared a potassium ion-selective optode that was employed 
in the development of the sensor. Potassium ionophore III (BME 44) has been 
shown to be a reliable and selective potassium ionophore (208, 212), and hence, 
was chosen as the sensing element for our catheter sensor.  In addition, we 
decided to employ PVC as the polymeric material for the preparation of the 
sensor given its chemical inertness, strength, and ease of use with ionophores 
(213).    
Due to the harsh and suboptimal in vivo conditions, suitable materials play 
a key role in the development of an in vivo sensor. Fiber optics can be 
manufactured in a variety of diameters and lengths while exhibiting great 
flexibility and maintaining functionality, thus offering a strong foundation for such 
a sensor.  In addition, the development of an optimal in vivo detection device 
would require a small, durable, and biocompatible components (206), all of which 
are met by a fiber optic. By uncasing a typical optical fiber to leave only the 
cladding and core, the fiber diameters can be fabricated on the order of 
micrometers, allowing for dimensions to be tuned for in vivo use, more 
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specifically able to be introduced through a small heart catheter.  As catheter 
based systems, such as the Transpac® IV Monitoring Kit (Hospira, Lake Forest, 
IL), are already currently used for invasively measuring the patients 
hemodynamic and cardiovascular status, the potassium sensor could be easily 
integrated into a typical point-of-care monitoring setup.  
Along with cooperation from Ocean Optics Inc. (Dunedin, FL) a custom 
made portable instrumental set-up was developed. Using a miniature fiber optic 
spectrometer, small light source, and a laptop computer the system can be 
moved and set-up with ease. The small size of the system makes its use 
possible even in tight spaces and areas which are already crowded with other 
instruments.  This allows for easy accommodation for point-of-care, operating 
rooms or other situations requiring immediate potassium monitoring and 
detection.   
EXPERIMENTAL PROCEDURES 
Materials.  9-(Diethylamino)-5-(2-octadecylamino)benzo[a]phenoxazine (proton 
chromoionophore III, ETH 5350), 2-dodecyl-2-methyl-1,3-propanediylbis[N-[5’-
nitro(benzo-15-crown-5)-4’-yl]carbamate] (BME 44, potassium ionophore III),  
valinomycin ( Cyclo(L-Val-D-HyIva-D-Val-L-Lac-)3: HyIva = α-Hydroxyisovaleric 
acid, Lac = Lactic acid), potassium tetrakis[3,5-bis-(trifluoromethyl)phenyl]borate 
(KTFPB), high molecular weight poly(vinyl chloride) (PVC),  bis(2-ethylhexyl)-
sebacate (DOS), and Selectophore-grade tetrahydrofuran (THF) were obtained 
from Fluka (Milwaukee, WI).  Tris(hydroxymethyl)aminomethane, molecular 
biology grade was obtained from Serva Chemicals (Heidelberg, Germany).  
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Potassium Chloride and Human Serum type AB (Male) were obtained from 
Sigma (St. Louis, MO). Swine whole blood was obtained from Innovative 
Research (Southfield, MI). A Transpac® IV Monitoring Kit was obtained from 
Hospira (Forrest Park, IL). All aqueous solutions were prepared using 16 MΩ 
deionized distilled water produced by a Milli-Q water purification system 
(Millipore, Bedford, MA). Solutions were kept at 37 oC by an 8000 series heating 
circulator from Polyscience (Niles, IL).  Potassium standards were prepared in 
0.500 M Tris/HCl pH 7.4.  A custom made fiber optic system consisting of 
Spectrasuite software, a one meter long, 300 μm in diameter fiber optic cable, a 
two meter long, 200 μm in diameter bifurcated fiber optic cable, 1 meter uncased, 
a 400 μm in diameter fiber optic cable, filter holder, PX-2 Xenon light source, and 
USB4000 miniature fiber optic spectrometer were obtained from Ocean Optics 
Inc. (Dunedin, FL).  600 nm optical filter was obtained from Chroma Technology 
Corp. (Rockingham, VT).   
Preparation of Optode Membranes and Immobilization on Fiber Optic. 
Membrane cocktails were prepared with the following composition:  0.5 mg 
Chromoionophore III, 0.81 mg KTFPB, 1.74 mg BME 44, 19.04 mg PVC, 38.10 
mg DOS dissolved in 357 μl THF (214)and vortexed to dissolve.  Prior to the 
deposition of the optode membrane on the fiber optic tip, the tip was 
functionalized with silanol groups to provide for the covalent linkage of the 
membrane to the fiber optic.  The fiber optic was soaked in 1.0 M NaOH for one 
hr and then soaked in 3-(trimethoxysilyl)propyl methacrylate for 3 hrs. The tip of 
the uncased, 400 μm in diameter, fiber optic cable was then dip coated in the 
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membrane cocktail by dipping the fiber optic in the cocktail for 2 s, removing to 
allow to dry, and then repeating this dipping/drying process for a total of 10 times.  
The membrane cocktail was allowed to dry for one hr and then the fiber was 
dipped a second series of times.     
Experimental Setup.  A one meter long, 300 μm in diameter fiber optic cable 
connected the xenon source to the filter holder which housed a 600 ± 10 nm 
filter.  One arm of the two meter long, 200 µm in diameter bifurcated fiber optic 
cable connects the filter holder to the single uncased 400 µm fiber optic that is 
used to measure the potassium in solutions. The other arm of the bifurcated 
cable is attached to the portable spectrometer connected through an USB port to 
a computer.  The experiments requiring a temperature of 37 oC were held 
constant at the desired temperature by a water circulator.  Smaller vials 
containing the solution of interest were positioned inside the circulating vial 
maintained at the desired temperature. The solutions to be measured and the 
end of 400 µm uncased fiber optic on which the optode membrane was 
immobilized were covered with a black sheet to avoid influence on the 
measurements from outside light sources.  The settings for the Spectrasuite 
software were as follows: 200 ms integration time, 75 scans to average, and 
boxcar of 100.  The dark reading was cancelled out using the scope minus dark 
mode.   
Response Time Measurements.  The response time of the sensor was 
determined in order to ensure adequate time was allotted for the sensor to 
respond before the reading was taken.  The tip of the sensor was submerged in 
129 
 
20 mL, stirred solution of 0.05 M Tris/HCl pH 7.4 and allowed to equilibrate.  
Readings were taken continuously.  Then this buffer solution was spiked with two 
mL of 0.1 M KCl, 0.05 M Tris/HCl pH 7.4, corresponding to 9.1 mM change in the 
potassium concentration.  Readings were monitored until the fluorescent reading 
was constant. 
Potassium Dose Response.The sensor was used to monitor changes in 
potassium concentrations in 0.05 M Tris/HCl pH 7.4, artificial serum, human 
serum and swine whole blood.  All calibrations were carried out in identical 
fashion substituting only the solution in which the calibration was taken. The 
temperature of designated experiments was also controlled with the previously 
mentioned water circulator. Artificial serum was prepared with the following 
concentrations:  5x10-4 M NaHSO4, 8x10
-4 M MgCl2, 3x10
-2 M NaHCO3, 9.5x10
-4 
M NaH2PO4, 1.4x10
-1 M NaCl, and 2.5x10-3 M CaCl2.  One mL of the solution of 
interest was added to each of three small glass vials while being stirred 
continuously. After the solution was at the desired temperature the initial reading 
was taken in the solution in triplicate.  The sensor was briefly removed from the 
solution and each vial was then spiked with 20µL of 0.1 M KCl 0.05 M Tris/HCl 
pH 7.4. The sensor was then replaced and allowed to equilibrate for 2 min, and 
the measurement with the new concentration was taken.  This procedure was 
repeated until the desired concentration was reached.  An excitation light of 600 
±10 nm was used and the emission was measured at 683 nm.  Initial potassium 
concentrations of biological fluids were determined by a K+ specific ion-selective 
electrode (205).   
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Sensor stability and conditioning.The sensor was left in human serum for 5.5 
hrs to demonstrate the sensors reliability for a significant length of time.  The 
sensing optode was placed in the human serum at 37 oC, while stirring, and the 
fluorescent response to the initial potassium concentration was recorded.  The 
sensor was then removed from the initial solution and placed in a new serum 
solution spiked with the potassium concentration corresponding to a 2 mmol/L 
increase.  This process was repeated to a final concentration 6 mmol/L higher 
than the initial potassium concentration and through the physiological range of 
potassium.   After completion of a series of concentrations the sensor was left in 
the serum at 370 C until the next dose-response was to be evaluated with the 
same prepared standards.  The conditioning of the sensor was performed in the 
same serum solution used for the dose-response.  The sensor was incubated in 
the potassium containing serum solution at 37 oC for one hr before the first dose-
response was evaluated.  
RESULTS AND DISCUSSIONS 
 We have developed a potassium sensor based on a lipophilic optode 
membrane, containing a potassium ionophore (BME 44) and a proton 
chromoionophore (ETH 5350). The electron neutrality condition of the membrane 
promotes an ion-exchange mechanism where potassium ions bound by the 
potassium ionophore exchange with the hydrogen ions bound by the proton 
chromoionophore in the membrane.  KTFPB, an anionic lipophilic additive is 
present to assist in the partition of the ions in and out of the membrane while 
DOS is used as a plasticizer for the PVC membrane.   The capture of potassium 
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ions from the sample by the membrane results in the release of protons of the 
same total charge out of the bulk of the membrane.  The resultant pH change 
occurring in the membrane can be monitored by observing the intensity of the 
fluorescent emission peak of the protonated form of the chromoionophore at 
~683 nm, and thus, allowing for the quantification of the potassium ions in the 
solution of interest.  As stated, the emission spectra of the protonated form of the 
chromoionophore is monitored, therefore as the potassium concentration 
increases, the fluorescent intensity of the emission peak decreases.  The 
equilibrium reaction is represented as follows: 
K+(aq) + L(org) + CH
+
(org) + R
-
(org) LK
+
(org) + C(org) + H
+
(aq) + R
-
(org)  
where L represents the potassium ionophore, C represents the 
chromoionophore, and R- represents the anionic lipophilic additive (210). A more 
descriptive explanation of this mechanism has been described previously (215-
216). BME 44 has been shown to be sensitive and selective for potassium (212), 
while PVC provides optimal mechanical characteristics for use in the sensing 
membrane (213). 
An uncased 400 µL in diameter fiber optic cable with the optode 
membrane immobilized on the tip was used for potassium detection. The fact that 
the fiber is uncased allows the diameter of the fiber optic to be small enough in 
dimension to allow for incorporation of the sensor into an existing commercially 
available heart catheter making possible its use for in vivo detection of whole 
blood potassium concentrations at or near the heart (figure 30). For the 
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A 
 
B 
 
Figure 30. A is a schematic for the experimental setup of the portable, fiber optic 
potassium sensor as the system could easily be incorporated with currently used 
heart catheters. B is the potassium sensing optode membrane immobilized on 
the tip of an uncased fiber optic is shown inside a Hospira Transpac IV 
Monitoring Kit. 
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characterization of the system in vitro, the tip of the fiber optic cable with the 
immobilized membrane was submerged in the solution of interest while being 
constantly stirred.  In order to perform experiments at physiological temperature 
we employed a water bath circulator to keep the solutions at 37 oC.  
Initially, the custom made, uncased, 400 µm in diameter, fiber optics 
intended for the optode immobilization were obtained with one inch of exposed, 
uncladded fiber optic core at the tip of the fiber.  It was hypothesized that this 
longer uncladded portion, on which the sensing membrane was immobilized 
would increased the surface area available for the deposition of the membrane 
and would allow for an amplified fluorescent signal, which should lead to a 
sensitive response.  However, upon further investigation it was discovered that a 
shorter uncladded portion of roughly one mm to even a completely cladded fiber 
optic allowed for a more sensitive response to the potassium ions as shown in 
figure 31.  It has been shown previously that removing cladding from a fiber optic 
and immersing in an aqueous solution can result in a loss of the fluorescent 
intensity measured.  This is not only due to a loss of the fluorescence light 
emitted as a response to potassium present, but also because there is a loss of 
excitation light traveling through the fiber (217).  In our case, with the one inch of 
exposed fiber optic, a large amount of the excitation and fluorescent emission 
was lost through the uncladded sides of the fiber optic therefore, the potential 
gain due to the increased surface area of the uncladded fiber optic did not 
contribute it the manner that we had expected.  Once the shorter fiber was  
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Figure 31.Dose-response comparing the difference in emission intensity of the 
optode at 683 nm with respect to the different potassium concentrations 
experience by a fiber possessing either a one inch or 1 mm uncladded core at 
the tip.  Points are the average of 3 readings ± 1 standard deviation and 
normalized with maximum value being equal to 1. Error bars not visible are 
concealed by the points of the graph. 
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employed, the light could be focused more efficiently to the tip of the fiber optic 
where the subsequent fluorescence resulting from the excitation of the 
membrane could be more efficiently detected, leading to a more sensitive 
response than that obtained with the longer, one inch uncladded fibers.   
We also evaluated the time required for the sensing membrane to reach 
equilibrium to assess the system’s capability for real time blood potassium level 
monitoring.  For that, the sensor was exposed to an initial artificial serum solution 
and then spiked with 0.1 M KCl, 0.05 M Tris/HCl solution corresponding to 
roughly a one order of magnitude change in the potassium concentration of the 
solution.  The fluorescent emission at 683 nm was monitored continuously as the 
optode responded.The response time of the optode membrane was found to be 
very fast.  Roughly, 100% of the change in fluorescence intensity was observed 
after 60 s of exposure of the optode to the solution of interest, as it can be seen 
in figure 32.  This fast response times allows for the sensor to provide physicians 
with real time feedback in the detection of small changes of a patient’s potassium 
levels. 
The normal physiological range of serum potassium ranges from 3.5-5.5 
mmol/L  (log[K+]= (-2.45)- (-2.26)) and even minor deviations from this range can 
lead to severe conditions (218).  Hypokalemia, or decreased serum potassium 
levels, less than 3.0 mmol/L, are an indication of a high level of intracellular  
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Figure 32.  The response time of the sensor was measured by continuously 
monitoring the change in emission at 683 nm after the addition of potassium to a 
final increase in concentration of 9.1 mM.   
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Depletion, and can result in acute neuromuscular symptoms (204).  Elevated 
serum potassium level or hyperkalemia, presents potassium levels greater than 
7.5 mmol/L, and also has serious effects with symptoms ranging from mental 
confusion, weakness, slowed heart rate, flaccid paralysis of the extremities, 
andeventually cardiac arrest, among others. Levels greater than 10 mmol/L 
typically result in death of the individual (204).  In order to investigate our 
system’s ability to respond in a linear fashion with respect to changes in 
potassium concentration through the desired concentration range, the fluorescent 
emission at 683 nm was monitored as the solution was spiked with 0.1 M KCl, 
0.5 M Tris/HCl pH 7.4.   The sensor was shown to be effective in monitoring 
changes in potassium levels of a buffered solution, artificial serum, human serum 
and swine whole blood within a large dynamic range.  When the buffer solution 
was spiked with known concentrations of potassium ions the response of the 
sensor was linear, decreasing as the concentration of potassium ions increased 
over several orders of magnitude well beyond the normal, elevated, or depleted 
physiological serum potassium levels (figure 33).  The sensor was then observed 
through the potassium range of interest using the artificial serum described 
previously to study the effect of any possible interfering ions.  Again, the sensor 
responded in a linear fashion as a result of the changes in potassium 
concentration.  The response of the sensor was bidirectional and was not 
affected by whether the change in potassium concentration happened in an 
increasing or a decreasing manner (figure 34).  The performance of the sensor 
was also not affected by temperature, as changing the temperature from room  
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Figure 33.  Fiber optic optode sensor response to different potassium 
concentrations in a Tris/HCl pH 7.4 buffered solution.  All points are the average 
of 3 measurements ± 1 standard deviation.  Error bars not visible are concealed 
by the points of the graph. 
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Figure 34. Fiber optic optode sensor response to different potassium 
concentrations in artificial serum at room temperature, with changes occurring 
both in an increasing and decreasing fashion.  All points are the average of 3 
measurements ± 1 standard deviation.  Error bars not visible are concealed by 
the points of the graph. 
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temperature to 37 oC did not adversely affect the performance of the system 
(figure 35).  While human serum and blood introduce several other possible 
interfering substances with the presence of a diverse range of proteins and 
complex matrix constituents, the sensor was able to maintain the precise linear 
response to potassium as in buffer.  Moreover, it did not exhibit any deviation 
from the expected performance when employed in human serum (figure 36) or 
swine whole blood at physiological temperature (figure 37).   As shown, the 
physiological range of potassium concentrations is encompassed by the dynamic 
range of the sensor, indicating that this sensor is practical for the detection of 
potassium in clinically relevant physiological fluids.  
Given that the sensor could be potentially used for in vivo monitoring of 
potassium levels in situations such as surgery, the long term stability needed to 
be investigated.  Since the sensor would need to be inserted in or near the heart 
and in contact with blood, it was postulated that biofouling may become an issue 
of concern.  To test the long-term stability and reproducibility of the sensor, the 
sensor was placed in human serum at 37 oC and a dose-response plot was 
obtained.  Then, the sensor was kept in this serum for up to 5.5 hrs and the 
sensor’s performance was evaluated at several points throughout the time period 
with respect to the response to the different serum potassium concentrations.  It 
was observed that the initial sensor response to potassium was roughly 9.3% 
higher than the subsequent sensor response after the optode had been exposed 
to serum (figure 38).  We believe that this may be due to the non-specific binding 
of serum proteins on the sensing optode surface and the resultant interference in  
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Figure 35. Fiber optic optode sensor response to different potassium 
concentrations in artificial serum at 37 oC.  All points are the average of 3 
measurements ± 1 standard deviation.  Error bars not visible are concealed by 
the points of the graph. 
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Figure 36. Fiber optic optode sensor response to different potassium 
concentrations in human serum at 37 oC.  All points are the average of 3 
measurements ± 1 standard deviation.  Error bars not visible are concealed by 
the points of the graph. 
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Figure 37. Fiber optic optode sensor response to different potassium 
concentrations in swine whole blood at 37 oC.  All points are the average of 3 
measurements ± 1 standard deviation.  Error bars not visible are concealed by 
the points of the graph. 
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Figure 38.  The response of the sensor with respect to time over an extended 
period of time with the sensing membrane exposed to human serum.  The 
sensing membrane was not exposed to serum prior to the initial potassium 
measurements.  All points are the average of 3 measurements ± 1 standard 
deviation.  Error bars not visible are concealed by the points of the graph. 
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Figure 39.  The response of the sensor is shown over an extended period of time 
in human serum.  The first measurement was recorded after a brief conditioning 
of the sensing optode to human serum. All points are the average of 3 
measurements ± 1 standard deviation.  Error bars not visible are concealed by 
the points of the graph. 
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the binding of the potassium by the optode’s ionophores.  However, after a brief 
exposure of the optode to the serum most of the available non-specific sensing 
surface was blocked by the serum proteins, consequentially allowing a 
reproducible sensor response to potassium to be observed as shown in figure 
39.  The sensor was consistently able to produce reproducible readings 
corresponding to the potassium concentration in the human serum over the 
extended period of time the sensor was in the solution.  Knowing this, for 
practical purposes, we can incorporate an algorithm in the calibration system to 
account for this difference or pre-condition the sensor before use.   
CONCLUSIONS 
We have demonstrated the design and development of a portable, real-
time, in vivo potassium monitoring sensor that could greatly benefit patients in 
variety of clinical settings.  Furthermore, the sensor, based on an optode 
membrane immobilized on the tip of a fiber optic has suitable dimensions for 
integration with a heart catheter.  The fast response time allows for changes in 
potassium levels to be monitored in real-time as they occur.  The sensor reacts 
reproducibly and reversibly at normal physiological blood potassium levels as 
well as in hypo- and hyperkalemia conditions (206), hence exhibiting the 
necessary characteristics for clinical use.  The stability of the sensor over time 
also shows promise for monitoring potassium levels in a variety of medical 
procedures, such as those related to interventional cardiology and surgery where 
real time monitoring of potassium may be crucial.  
 
Copyright © Daniel F. Scott 2011 
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CHAPTER SEVEN 
 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
As advancements in molecular engineering techniques and improvements 
in instrumentation continue to evolve, so too will the use of bioluminescent 
proteins in analytical applications.  Over the past ten years, the sensitivity of CCD 
cameras and other luminescent detectors has greatly improved.Their cost has 
also decreased, making systems capable of detecting only a few light emitting 
molecules readily available for investigators (219).  This, along with the 
miniaturization of instruments, has allowed for the integration of the luminescent 
detectors into miniaturized detection systems such as lab-on-a-chip and lab-on-
a-CD type devices (220).  As the push for faster, portable, and more robust 
detection capabilities continues for point-of-care and on-site analysis, these 
systems provide many of the desired characteristics.  The ability for multiplexed 
analysis of samples in these miniaturized devices would further increase the 
versatility and value of these systems to the scientific community.   
To that end, Chapter Three describes the simultaneous multiplexed 
detection of three pro-inflammatory cytokines in physiological fluids through the 
clinical range of interest.  Previous multiplexed detection with bioluminescent 
labels has been reported and there are several methods which have allowed 
more than one analyte to be detected in a single sample. These include 
separating the emission spectra by using two different, individual luminescent 
proteins (123-125), using genetically engineered proteins to achieve spectrally 
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diverse emission profiles (96, 126), orallowing the differentiation of the signals 
through time resolution (100).  All of the previous studies, although very 
innovative and important, are limited to two analytes.  Our study combines time 
and wavelength resolution to create three distinct time/wavelength windows to 
allow the successful resolution of three separate bioluminescent signals in a 
single solution.  This is the first time that a single bioluminescent protein has 
been able to quantify three separate analytes simultaneously.  The cytokines of 
interest (IL-1β, IL-6, and IL-8) were each individually genetically fused to a 
selected aequorin mutant to create three new proteins.  The resultant proteins 
were expressed in E. coli and purified.  Each interleukin-aequorin fusion protein 
was characterized with respect to emission profile and decay kinetics with nine 
different coelenterazine analogs.  The selected semi-synthetic interleukin-
aequorin fusion proteins gave a spectral separation of 54 nm in their emission 
maximum and a half-life difference of 13.68 s, sufficient to resolute all three 
signals simultaneously.  An assay was then developed that was capable of 
detecting all three targeted proteins in a single well with detection in the clinically 
relevant range. 
Future work to extend the findings presenting inChapter Three would 
focus on several areas.  The first would be to incorporate the use of aequorin and 
multiplexed detection into a miniaturized device.  Aequorin has previously been 
shown to be compatible with miniaturized device platforms (220).  Thus the initial 
next step would be to transfer the developed microtiter plate assay to a 
miniaturized lab-on-a-CD platform.  A CD mold with the desired microchannels, 
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reservoirs, and burst valves would need to be constructed and tested, and then 
the assay scaled down to appropriate volumes and incubation times.  Again as a 
proof of concept the multiplexed cytokine detection would serve as an excellent 
template to start with as the fusion protein constructs and purification procedure 
are already established.  Further extension and new applications could also 
include other clinically relevant diagnostic tests such as DNA hybridization 
assays able to quickly and efficiently differentiate unique influenza strains.  As 
new influenza strains continue to emerge, the ability to quickly determine which 
strain a patient has contracted could offer valuable information that would 
determine the subsequent treatment and physicians recommendations.  The 
bioluminescent labels would offer the sensitivity to label the DNA probes 
efficiently and allow detection in the µL or less volume required for the 
miniaturized devices. 
Additional attention should also be directed towards the continued 
identification and synthesis of new aequorin mutants and coelenterazine 
analogues with favorable characteristics.  The development of a coelenterazine 
analogue that shifted the aequorin emission to the higher energy, shorter 
wavelength region while maintaining the longer half-life would allow the current 
multiplexed assay to immediately be expanded to four analytes.  Currently, the 
spectral overlap of the shortest wavelength and long half-life semi-synthetic 
aequorin (F113W mutant with coelenterazine i, 484 nm emission max and 11.65 
s half-life) make to resolving the signal from either the longer or shorter 
wavelength peaks obtained with the interleukin fusion proteins extremely difficult.  
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One potential option would be if a coelenterazine analogue was constructed that 
combined the iodine substitution in the C2 position to retain the longer half-life 
with one of the alterations at the C8 position that has lead to the higher energy 
emission with previous coelenterazines.  Pairing this coelenterazine with one of 
the current aequorin mutants that show a more blue shifted emission, such as 
the F113W mutant, could possibly result in a semi-synthetic mutant with an 
emission maximum near 450 nm while still possessing a long half-life.  Further 
investigation into aequorin mutants with multiple mutations and continued 
random mutagenesis could also lead to variants capable of filling this void and/or 
shifting the emission further towards the red region to allow even more targets to 
be labeled simultaneously with aequorin.   
Chapter Four outlines the use of a new semi-synthetic aequorin mutant 
that was shown to improve the labeling and imaging capabilities of aequorin.  
Instead of a genetic conjugation, a chemical conjugation through a unique 
cysteine created in the protein was employed.  The cysteine was usedto attach 
the protein to an anti-CD33 monoclonal antibody capable of recognizing the 
CD33 antigen expressed on the surface of AML cells. Excellent detection of free 
CD33 was achieve, well below the limits necessary to detect the recently 
discovered, clinically relevant concentrations (158), with the aequorin labeled 
antibody complex.  Whole AML cells could also to be detected by the complex 
down to three cells.  Both of these assays were developed on a microtiter plate 
format in order to allow quick screening of a large number of samples.  
Additionally, the ability to image with this new semi-synthetic aequorin was also 
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investigated.  A distinguishable signal was observed from the protein for up to 
approximately three minutes after the initiation of the bioluminescent reaction on 
an imaging microscope.  Light emitted from the antibody-aequorin complex 
bound to the surface of AML cells could also be visualized with the setup.   
Future considerations for this project have several potential pathways for 
investigation.  Initially cellular imaging with this and similar aequorin molecules 
would benefit greatly from custom instrumentation.  All of the reported imaging 
results were obtained on an imaging microscope typically used with fluorescence 
imaging, and thus the setup was not optimal for bioluminescence imaging.  The 
sample platform was not isolated from outside light, and while the microscope 
was located in a small room with no windows, inherent light from the computer 
monitor and light leaking underneath the door was evident.  Although they did not 
completely eliminate the problem, black sheets covering the door and computer 
and a custom black box placed on the observation platform did aid with this 
issue.  Additionally, a very rough injection system was created from available 
materials and was not completely conducive to the experimental procedure.  
Dislodging of the immobilized cells was continually observed with the injection of 
the Ca2+ solution, which made it extremely difficult to focus on a specified point to 
collect light, as many times the cells and bioluminescence attached to their 
surface were not completely stationary throughout the camera exposure.  It is 
speculated that a custom instrumental setup with a sample platform isolated from 
outside light and an injection system would allow high quality images to be 
collected.  With this new instrumental setup or a similar one, in vivo imaging with 
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the aequorin labeled antibody for the detection of AML in a laboratory animal 
could be examined.  As stated previously, aequorin bioluminescence imaging 
has been limited with respect to imaging outside of Ca2+ applications; thus, the 
ability to label an antibody and image the location with aequorin would provide 
the necessary incentive to move forward with future imaging applications of 
aequorin.   
Once successful with the in vivo imaging, multiple surface antigens or 
complementary analytes could be targeted through the use of several semi-
synthetic aequorins, similarly to the multiplexed cytokine detection above.  The 
confirmation that aequorin immunolabels can bind and quantify surface antigens 
allows a similar system to be employed for other disease prognoses and 
monitoring applications. This application extends beyond the imaging and could 
also be simplified to a microtiter plate platform as seen with the preliminary CD33 
on AML cells monitoring.  For example, the literature has shown that the cell 
surface antigens CD25+ levels ofCD19 expressing cells can provide important 
information with regard to HIV infection disease stage and activity (221).  The 
ability to monitor these levels on the cell surfacequickly and efficiently could 
provide valuable information in terms of evaluating the activation and course of 
the disease, patient prognosis, and therapeutic options.  A multiplexed microtiter 
plate assay could be developed to screen cells for the levels of these two 
important surface markers on the whole cells, without the need to separate 
different cellular components.  Similarly, cell surface sialic acid presentations 
have recently been shown to be effective indicators for a number of disease 
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infections, states, and susceptibility including influenza and malaria (222). Thus 
by targeting these surface antigens with aequorin immunolabels, not only can the 
physical state of the disease be addressed, but also the possibility of examining 
processes such as infection pathways and mechanisms in an effort to create new 
therapeutic options.   
Chapter Five discusses the creation of a bioluminescent molecular switch 
capable of monitoring cAMP.  The switch was constructed by genetically splitting 
and subsequently attaching the two fragments of aequorin to the N- and C-
termini of cAMP receptor protein (CRP).  CRP undergoes a conformational 
change upon the selective binding of cAMP which causes the repositioning of the 
attached aequorin fragments, resulting in a loss of bioluminescent signal.  The 
molecular switch was shown to be capable of monitoring changes in cAMP 
concentration over several orders of magnitude, in addition to the ability to detect 
changes in cellular cAMP concentrations due to external conditions.  Future 
extension of this work could include the use of the molecular switch to monitor 
the cellular movement and presence of both cAMP and CRP during specific 
cellular processes or in response to external stimuli.  CRP levels have been 
shown to correlate to disease states of certain cancers (223). The ability to 
monitor where these proteins are and at what stages they are binding cAMP 
could lead to valuable insight into the disease progression and signaling 
pathways.  Additionally, cAMP has been associated with the regulation of Ca2+ 
channels and Ca2+ entry into the cell (224).  Consequently, a complex capable of 
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responding to both cAMP and Ca2+ could offer previously unavailable information 
as to some of the specifics of the cellular signaling cascade.  
Chapter Six offers a glance into the versatility of fluorescent based 
systems as well.  A fluorescent fiber optic potassium sensor was 
customdesigned and developed to allow a patient’s potassium concentration to 
be monitored in real time at the point of interest.  The system is comprised of a 
custom made, portable instrumental setup consisting of an undersized light 
source and spectrophotometer run by a laptop computer, allowing the system to 
be easily moved and positioned in a crowded working area.  The sensing 
membrane is immobilized on the tip of an uncased fiber optic, the dimensions of 
which easily allow for the incorporation of the sensor through a typical heart 
catheter.  The potassium sensor was able to response linearly, reversibly, and 
consistently through the relevant range of potassium concentrations in both 
serum and whole blood.  In addition, the ability to monitor potassium 
concentrations over an extended period of time was also demonstrated.  The 
future of this project lies in the clinical testing and use of the sensor.  The sensor 
would first need to be tested with laboratory animals and could easily be 
incorporated into an existing catheter laboratory procedure.  The exposure time 
and positioning of the sensor would need to be optimized.  A possible method to 
extend the stability of the sensor further would be to engineer the tip of the 
sensor to rest in an isolated chamber at the end of the catheter.  When a reading 
was desired, the blood could be drawn in and exposed to the sensor for the 
necessary amount of time and then flushed back out of the chamber.  This would 
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prolong the lifetime of the sensing membrane and discourage biofouling.  After 
the initial testing and optimization of the sensor, this work could be expanded by 
the development of similar sensors for other ions of interest.  There are several 
commercially available ionophores for other ions such as sodium, hydrogen, 
calcium, and iron.  The incorporation of these ionophores into similar membrane 
cocktails would allow the sensor to be tailored to these other clinically relevant 
ions.  Once the individual sensors have been developed and optimized, the 
nature of the fiber optics would allow the bundling of the individual fibers to 
create a single, insertable fiber that could monitor all of the desired ions 
simultaneously.  This could greatly simplify the task of patient monitoring in a 
clinical setting and allow real time, in vivo measurements that would improve the 
physician’s therapeutic considerations and diagnostic abilities, and in turn 
improve patient care.   
As the work presented in this dissertation is expanded upon, new 
obastacles to overcome and issues to consider will undoubtedly arise.  In the 
case of in vivo imaging with any aequorin based system, the presence and 
requirement of Ca2+ throughout the body will require special attention to prevent 
the spontaneous emission of light as soon as the aequorin complex is introduced 
into the body.  If a fixed cell population were to be used to model in vivo 
response, an EDTA containing media could be employed to prevent premature 
light emission.  However, if actual, in vivo investigation is desired, other 
considerations must be examined.  One possible avenue around this would be to 
introduce the apo form of the protein that does not have the coelenterazine 
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already bound in the hydrophobic pocket.  Thus, when Ca2+ is bound by 
aequorin, the coelenterazine will not be excited before the aequorin complex has 
arrived at the desired location.  Once the aequorin has been targeted to the 
required location, coelenterazine can be introduced into the subject to allow the 
production of light. The introduction of coelenterazine into the organism to be 
examined also brings new issues into the equation.  Coelenterazine is very 
expensive, thus injecting enough to circulate throughout the blood stream of an 
animal or human to trigger the bioluminescent reaction with aequorin would not 
be very cost efficient.  To overcome this problem, the investigation could be 
localized to a contained area that was readily accessible to an injection. Thus, 
the need to inject a mass amount of coelenterazine could be eliminated.  The 
aequorin complex could be introduced into the localized area and allowed to bind 
the targeted molecules and then coelenterazine injected to trigger the 
bioluminescence reaction.   
Overall progress in the area of luminescent monitoring and detection has 
greatly advanced as exemplified by many novel technologies.  Other examples 
include antibody coated magnetic beads that have been used to capture specific 
bacteria on a microfluidic device, which were then quantified indirectly with firefly 
luciferase (225).  Whole cell biosensors with engineered E. coli cells have been 
incorporated into lab-on-a-chip setups that have shown their ability to rapidly 
monitor environmental and water pollutants in samples (226-227).  Firefly 
luciferase has also been employed in a lab-on-a-chip metabolic profiling system 
able to detect ATP down to sub-micromolar ranges (228).   
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The work presented in this dissertation illustrates how luminescent 
molecules can be tailored to enhance and progress detection capabilitiesfurther.  
These types of demonstrations will continue to expand the boundriesof what is 
thoughtpossible with regard to understanding of molecular and cellular events 
and to their applications in the detection of biomedical samples.In addition, as the 
discovery and characterization of new bioluminescent proteins and the genetic 
modification of current bioluminescent proteins continues to expand the spectral 
diversity and favorable characteristics, the employment of bioluminescent 
proteins will also grow.  Above all, luminescent molecules are a fascinating 
natural phenomenon that when coupled with modern instrumentation and 
reagents results in bioanalytical methods with exceptionally low detection limits.  
Recent discoveries of bioluminescent organisms and plants living in the depths of 
the Antarctic waters and in the rain forests will undoubtedly provide researchers 
with a myriad of new proteins that will have many applications in bioanalysisin 
the near future.   
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